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ABSTRACT 
 
Alzheimer’s disease (AD) is a devastating neurodegenerative disorder, characterized by 
neuronal loss and gradual cognitive impairment, a serious public health problem, affecting more 
than 30 million people worldwide. The presence of two well-known abnormal protein aggregates 
in cerebral cortex and hippocampus characterize AD pathologically: senile plaques in specific 
areas of the brain, extracellular, and composed of insoluble A peptides; and neurofibrillary 
tangles, intracellular aggregates, mostly consisted by hyperphosphorylated Tau, a microtubule-
associated protein localized in axons. Several authors have described for decades that protein 
aggregation process can induce toxicity for neurons causing synaptic dysfunction, 
neuroinflammation and oxidative stress. One major aspect of AD pathology, that is observed in 
both humans and mouse models of the disease is the accumulation of senile plaques, containing 
A peptides, leading to a neuronal dysfunction and cell death. Neuronal cell survival depends on 
a health and effective mitochondrial quality control, but also a balance between autophagic and 
lysosomal pathways. Data has demonstrated the crucial role of both macroautophagy (referred to 
here as autophagy) and lysosomal pathways in maintaining cellular homeostasis, as well in 
neuronal survival, degrading and decreasing the amount of misfolded proteins and impaired 
organelles, like that preventing the accumulation of toxic protein aggregates. Beclin-1 is a protein 
involved in several biological functions so relevant in several human diseases, such as heart 
disease, pathogen infection, development and neurodegenerative disorders. However, as one of the 
main proteins responsible of autophagy regulation, it has been shown that Beclin-1 levels are 
reduced in AD patient’s brain. For several years, a lot of research has been focused on a family of 
protein deacetylases, Sirtuins (SIRTs), and its crucial role in a variety of cellular biological 
systems, including neuroinflammation, melanocortin system, energy balance, the ubiquitin-
proteasome system; and central nervous system regulation. SIRT1’s activity can influence 
autophagic pathway, acting on components of the autophagic machinery. Despite of this, it has not 
been described in neuronal cells the effect of SIRT1 on deacetylation of Beclin-1, which can result 
in deregulation of the autophagic pathway. Autophagy impairment plays a key role in sporadic 
Alzheimer’s disease (sAD) neurodegenerative process. Nevertheless, the mechanism(s) that lead 
to a deficiency in autophagy in AD remains elusive. In this work we identify, for the first time, 
that Beclin-1 acetylation status is responsible for autophagosomes maturation and is implicated in 
the alterations in autophagy observed in AD neurodegeneration. We observed that Beclin-1 is 
deacetylated by SIRT1 and acetylated by p300. In addition, Beclin-1 acetylation inhibits 
autophagosomes maturation, leading to impairment in autophagic flux. We also analyzed some 
proteins, known to be involved in the maturation of autophagosomes, such as Rab 7 that 
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participates in the fusion step with lysosomes. We observed that an overexpression of Rab 7 and 
the formation of large perinuclear lysosome clusters are in accordance with an increase in 
lysosomal biogenesis determined by an increase in LAMP-2A and Cathepsin D expression in sAD 
cells. Thus, our data provide strong evidence that Beclin-1 acetylation impairs the autophagic flux 
and despite lysosomal biogenesis is triggered as a compensatory response, autophagosome fusion 
with lysosomes is compromised contributing to AD neurodegeneration. 
Keywords: Alzheimer’s disease, Autophagic-Lysosomal Dysfunction, Beclin-1, SIRT1 and 
Deacetylation. 
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RESUMO 
 
A doença de Alzheimer (DA) é um distúrbio neurodegenerativo devastador, caracterizado 
por uma perda de neurónios e por um comprometimento gradual cognitivo, um grave problema de 
saúde pública, afetando mais de 30 milhões de pessoas em todo o mundo. A acumulação não normal 
de duas proteínas específicas no córtex cerebral e no hipocampo, caracteriza a DA 
patologicamente: as placas senis em áreas específicas do cérebro, depósitos extracelulares, e 
constituídos por peptídeos de -amilóide insolúveis; e as tranças neurofibrilares, agregados 
intracelulares, constituídos principalmente pela Tau hiperfosforilada, uma proteína associada aos 
microtúbulos, localizada nos axónios. Por várias décadas, diversos autores têm descrito que o 
processo de acumulação proteica, pode induzir toxicidade aos neurónios, levando a uma disfunção 
sináptica, a uma neuroinflamação e a um estresse oxidativo. Uma das características mais 
importantes da patologia DA observada quer em humanos, quer em modelos de ratinho que 
apresentam a doença, é a acumulação das placas senis, as quais contêm peptídeos ricos em proteína 
-amilóide, levando a uma disfunção neuronal e morte celular. A sobrevivência neuronal, depende 
tanto de um ótimo bem-estar e de um controlo efetivo de qualidade a nível mitocondrial, mas 
também de um equilíbrio entre as vias autofágica e lisossomal. Dados científicos têm demonstrado 
o papel fundamental de ambas as vias, a via da macroautofagia (designada aqui como autofagia) e 
a via lisossomal, na manutenção da homeostasia celular, bem como na sobrevivência neuronal, na 
degradação e diminuição da quantidade de proteínas disfuncionais e organelos deficientes, 
prevenindo assim a acumulação de agregados proteicos tóxicos. A Beclin-1 é uma proteína 
envolvida em várias funções biológicas e importante em diferentes patologias, como por exemplo, 
nas doenças cardíacas, na infeção por patógenos, no desenvolvimento e na neurodegeneração. No 
entanto, como uma das principais proteínas responsáveis pela regulação da via autofágica, foi 
demonstrado que os níveis de Beclin-1 estão reduzidos em cérebros de doentes com DA. Durante 
vários anos, a ciência focou-se numa família de proteínas de deacetilase de histonas, as Sirtuínas 
(SIRTs), e no seu papel de muito importância em diversos processos biológicos e celulares, 
incluindo na neuroinflamação, no sistema de melanocortina e no balanço energético, e no sistema 
proteossómico; e na regulação do sistema nervoso central. A atividade da SIRT1 pode influenciar 
o processo autofágico, atuando sobre os seus componentes presentes na maquinaria autofágica. No 
entanto, ainda não foi descrito o seu efeito de deacetilação na Beclin-1, em neurónios, podendo 
levar a um comprometimento do próprio processo autofágico. Um comprometimento por parte da 
autofagia vai desempenhar um papel crucial no processo neurodegenerativo da doença de 
Alzheimer do tipo esporádico (DAs). Contudo, o (s) mecanismo (s) responsável (eis) pela 
incapacidade da via autofágica na DA permanece inconclusivo. Neste trabalho identificámos, pela 
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primeira vez que o estado de acetilação da Beclin-1 é responsável pela maturação dos 
autofagossomas, e que está implícito nas alterações da via autofágica observada na 
neurodegeneração da DA. Verificámos que a Beclin-1 é deacetilada pela SIRT1 e acetilada pela 
p300. Para além disso, a acetilação da Beclin-1 inibe a maturação dos autofagossomas, levando a 
um comprometimento do fluxo autofágico. Também analisámos algumas proteínas, bastante 
conhecidas por estarem envolvidas na maturação dos autofagossomas, tais como a Rab7, a qual 
participa na etapa de fusão com os lisossomas. Observámos que uma sobre-expressão da Rab7 e a 
formação de grandes aglomerados lisossomais perinucleares estão de acordo com um aumento da 
biogénese lisossomal, determinada por um aumento na expressão de LAMP-2A e da Cathepsin D 
em células com DAs. Assim, os nossos resultados mostram fortes evidências de que a acetilação 
da Beclin-1 compromete o fluxo autofágico e, apesar da biogénese lisossomal ser desencadeada 
como uma resposta compensatória, a fusão dos autofagossomas com os lisossomas é prejudicada, 
contribuindo para a neurodegeneração da DA. 
Palavras-chave: Doença de Alzheimer, Disfunção Autofágica-Lisossomal, Beclin-1, SIRT1 
e Deacetilação 
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Sir2- Silent information regulator 2; 
SIRTs- Sirtuins; 
SIRT1- Sirtuin 1; 
SEM- Standard Error of the Mean; 
SGZ- Subgranular zone; 
SNARE- Soluble N-ethylmaleimide-sensitive factor activating protein receptor;  
SNC- Suprachiasmatic nucleus; 
SORL1- Sortilin-related receptor-1; 
SPs- Senile Plaques; 
SVZ- Subventricular zone;  
TBS- Tris-Buffered Solution; 
TGN- trans-Golgi network; 
UCP2- Uncoupling protein 2; 
ULK1- Uncoordinated (UNC)-51-like kinase 1; 
ULK2- Uncoordinated (UNC)-51-like kinase 2;  
UPS- Ubiquitin-proteasome system; 
UVRAG- Ultraviolet radiation resistance-associated gene; 
V-ATPases- Vacuolar H+ ATPases; 
Vps15- Vesicular protein sorting 15; 
Vps34- Vesicular protein sorting 34; 
WIPI- WD-repeat domain phosphoinositide-interacting protein.  
 
CHAPTER 1 
1 
 
 
 
1 INTRODUCTION 
 
1.1 Aging: a risk factor for neurodegenerative disorders 
 
Neurodegenerative diseases are a heterogeneous group of age-related disorders, which can 
be defined as hereditary or sporadic conditions (Peden and Ironside, 2012). Traditionally, these 
disorders are characterized by a selective loss of specific neuronal cells and aggregation, as well 
as deposition of misfolded proteins, a common mechanism shared by these types of maladies, 
leading to a chronic and progressive nervous system dysfunction (Skovronsky, Lee and 
Trojanowski, 2006). 
Aging, a time-dependent functional decline, results from the accumulation of damage 
molecules, cells and tissues during the lifetime, which often leads to a progressive loss of 
physiological integrity, preceded of an impaired function and an increased vulnerability to death 
(López-Otín et al., 2013). At first sight, aging is the biggest risk factor for many diseases, such as 
cancer, cardiovascular diseases and neurodegenerative disorders. 
Over the last century, life expectancy of the human population has increased and as a 
reflection the possibility of developing these specific disorders will increase exponentially over 
time (Walker and Jucker, 2015; Wyss-Coray, 2016). 
Numerous studies indicate that changing life-style factors, including a healthy diet, a low- 
calorie diet (caloric restriction), and specific micro/macronutrients as unsaturated fatty acids, 
might have beneficial effects on the aging process (Witte et al., 2009). Additionally, caloric 
restriction (CR) is a reduction of food intake without malnutrition, a key anti-aging intervention, 
that extends life-span in most animals so far tested, such as rhesus monkeys (Mattison et al., 2017), 
reducing the incidence of diabetes, cardiovascular disease, cancer, and brain atrophy (Rubinsztein, 
Mariño and Kroemer, 2011). 
Furthermore, it was shown in animal models of aging and neurodegenerative diseases, that 
CR could protect hippocampal, striatal and cortical neurons, and at same time ameliorated 
functional decline (Witte et al., 2009). At the same time, some epidemiologic and short-term 
human studies have supported CR health benefits, specifically the CR diet consumed by 
centenarians in Okinawa, Japan, which have been used as an argument to support the CR 
hypothesis in humans for contributing to healthy aging and longevity (Willcox et al., 2007). 
However, an excessive caloric intake, which is related to obesity has been associated with 
changes in brain structure, cognitive deficits, dementia, Alzheimer’s disease and Parkinson’s 
disease (PD) (Mazon et al., 2017). 
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Therefore, brain function can be optimized by intermittent dietary energy restriction, as well 
as exercise, and these types of energetic challenges enhance adaptive cellular stress-response 
signaling pathways in neurons involving neurotrophic factors, protein chaperones, 
deoxyribonucleic acid (DNA)- repair proteins, autophagy and mitochondrial biogenesis (Mattson, 
2012). 
 
1.2 Alzheimer’s disease 
 
In 1906, Alois Alzheimer, a German clinical psychiatrist and neuroanatomist reported for the 
first time “A peculiar severe process of the cerebral cortex” to the 37th Meeting of South-West 
German Psychiatrists in Tübingen, Germany (Hippius and Neundorfer, 2003). Alzheimer 
described the long-term study of Auguste Deter, a “51 years old woman” patient with striking 
symptoms: reduced comprehension and memory, disorientation, paranoia, aphasia and auditory 
hallucinations (Maurer, Volk and Gerbaldo, 1997), and the occurrence of histological alterations 
on her autopsy in the cerebral cortex, later-on known as senile plaques and neurofibrillary tangles 
(Alzheimer, 1991). 
Nowadays, Alzheimer’s disease (AD) is one of the most frequent neurodegenerative 
disorder, currently without an effective cure, treatment or prevention, affecting people in 
worldwide (Citron, 2010). AD is characterized by neuronal loss and gradual cognitive impairment 
and considered a critical public health issue. AD, as the major cause of dementia, in the elderly 
(Vinters, 2015) is defined by a cognitive impairment affecting mostly memory, language, 
behavioral and motor disturbances (Kovacs, 2014), that predominantly affects more women than 
men (Candeias et al., 2017), also number of AD cases expected to triple by the year 2050, without 
effective treatments (Huang and Mucke, 2012). 
As a multifactorial disorder, many factors have been linked to AD, such as exacerbation of 
aging; genetic inheritance; environment factors (diet and malnutrition); head injury, or exposure to 
aluminum; infectious agents; degeneration of anatomical pathways; a compromised blood brain 
barrier (BBB); mitochondrial and immune system dysfunction, all may contribute to development 
and progression of this malady (Armstrong, 2013) . 
Normally, patients with AD show an impaired ability to perform tasks on routine basis, and 
often experience psychiatric, emotional, and personality disturbances (Tarawneh and Holtzman, 
2012). 
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1.2.1 Neuropathology 
 
The two common and distinctive neuropathological “hallmarks” lesions present in selective 
brain regions of patients, the temporal and parietal lobes, as well in restricted regions within the 
frontal cortex and cingulate gyrus, characterize AD pathologically: 
(1) the senile plaques (SPs) composed of extracellular deposits of abnormal fibrillar insoluble β-
amyloid peptide (Aβ) in the brain parenchyma and in blood vessels of the brain; and 
(2) the neurofibrillary tangles (NFTs) formed by accumulation of intracellular aggregates of 
hyperphosphorylated and glycosylated Tau protein in dystrophic neurites, as neuropil threads, 
or as massive NFTs in neuronal cell bodies (Figure 1.1), a microtubule-associated protein 
involved in the promotion and stabilization of microtubules (Serrano-Pozo et al., 2011; Jack 
and Holtzman, 2013). 
 
Figure 1.1 Neuropathological Hallmarks of AD pathology. SPs- Senile plaques (arrows) and NFTs- Neurofibrillary tangles 
(arrowheads) Filipe, 2018. Immunohistochemistry stain Tau-C3 from a patient with AD (adapted from Binder et al., 2005) 
 
Several special staining techniques are used to identify neurons and neurofibrils. However, 
the Bielschowsky silver method is the most useful technique in the identenfication of multiple 
plaques subtypes of SPs, that have been described over the years, such as diffuse, primitive, 
neuritic, compact cored, and cotton-wool. Anyway, the neuritic plaques, in particularly, have been 
the most significant plaque type for the diagnosis of AD during autopsies (Castellani, Rolston and 
      Healthy Brain               Alzheimer’s disease Brain 
SPs 
NFTs 
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Smith, 2010). The SPs are normally interspersed among clusters of axons and dendrites (neurites), 
which are usually grossly swollen or atrophic (Nixon, 2007). 
In contrast, NFTs are a massive fibrillar intracytoplasmic inclusions in neuronal cell 
bodies/proximal dendrites, dense aggregates of long unbranched filaments, paired helical filaments 
(PHFs), which become extracellular ghost tangles after the death of the neurons. Additionally, 
NFTs are present in the cytoplasm of neurons, such as cortical pyramidal cells, in the entorhinal 
cortex, hippocampus, amygdala and among other regions. These filaments, are composed of 
microtubule- associated protein Tau in an abnormally phosphorylated manner, that self-assembles 
to develop, the PHFs. Besides that, these are seen in dystrophic neurites of plaques, as fine neuropil 
threads, reinforcing the correlation between density of NFTs and severity of dementia (Longstaff, 
2005). 
Regularly, they are present mainly in brain regions involved in learning and memory and 
emotional behaviors (Figure 1.2), meaning that an abnormal excessive accumulation of proteins 
in the brain can lead to loss of neurons and synapses, causing an atrophy in different parts of the 
brain (Mattson, 2004). 
 
                                                          Normal Brain                       Alzheimer’s Brain 
 
Figure 1:2 – The pathology of Alzheimer’s disease. a, Brain of a healthy person. b, Brain of an Alzheimer’s disease patient, 
which exhibits clearly marked shrinkage of gyri in the temporal lobe (lower part of the brain) and frontal lobes (left part of the 
brain). c and d, Positron Emission Tomography (PET) scans images showing glucose uptake (red and yellow indicate high levels 
of glucose uptake) in a living healthy person and a normal control subject. The Alzheimer’s patient exhibits large decreases in 
energy metabolism in the frontal cortex (top of brain) and temporal lobes (sides of the brain). Adapted from Mattson, 2004. 
 
Despite this, “plaques” and “tangles” are found in normal aged brains. When they are present 
as an abnormal excessive accumulation manner, this can play a critical role, affecting numerous 
cellular processes such as energy metabolism, synaptic transmission, generation of reactive 
oxygen species (ROS), cellular calcium and protein homeostasis; and then increasing the risk for 
developing AD pathology (Lu et al., 2015). 
Normal Brain Alzheimer’s Brain 
a b 
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1.3 Genetically 
 
AD is normally divided into two forms: familial or early-onset AD (2-10% cases), where 
individuals typically develop the disease before 60 years; and the so-called “sporadic” or late-onset 
AD (non-hereditary), that occurs late in life, over 60 years (Bertram, Lill and Tanzi, 2010). 
Mutations in three genes were identified as autosomal dominant forms of AD (rare genetic 
mutations): -Amyloid Precursor Protein (APP), Presenilin 1 (PSEN1) and Presenlin 2 (PSEN2), 
which are located on chromosomes 21, 14 and 1, respectively. 
All three mutations in APP, PSEN1 and PSEN2 (explain 2-10% of the occurrence of early- 
onset AD) are involved in the overproduction of A. As an example of the correlation between 
overproduction of A and dementia is the Down’s Syndrome (DS) or Trisomy 21, with a 
triplication of APP gene, where patients have an increased chance to develop early-onset AD 
(Head et al., 2012). 
On the other hand, late-onset AD pathology results from the interaction of environmental, 
genetic and epigenetic factors, indicating that gene polymorphisms may interact with 
environmental factors to predispose to AD (Van Cauwenberghe, Van Broeckhoven and Sleegers, 
2016). Several genes variations are involved in development of the late-onset AD, including the 
4 allele of the apolipoprotein E (APOE) gene, sortilin-related receptor-1 (SORL1), adenosine 
triphosphate (ATP)-binding cassette subfamily A member 7 (ABCA7) and among others.  
The 4 allelic variant of the APOE gene is the biggest risk factor for late-onset AD, located 
on chromosome 19 (Citron, 2010). The human APOE gene contains three polymorphic allelic 
variants at a single gene locus (2, 3 and 4) encoding for three ApoE isoforms (ApoE2, ApoE3 
and ApoE4). Normally, ApoE is originated essentially by the liver and macrophages in peripheral 
organs, mediating cholesterol metabolism in an isoform-dependent manner. However, in the central 
nervous system (CNS), ApoE is synthetized locally in the brain, mainly by astrocytes, transporting 
cholesterol to neurons via ApoE receptors. 
 Therefore, ApoE plays a crucial role in the CNS, including in neuronal development, in 
regenerating and in deposition or clearance of A by direct protein-to protein interaction (Posse 
de Chaves and Narayanaswami, 2008; Liu et al., 2013). 
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1.4 Amyloid- Protein (A) 
 
Over decades, studies have been supporting that an imbalance between the production and 
clearance of A occurs in a very early AD stage. As a normal cellular metabolism product is 
necessary a homeostatic balance between A production and clearance, crucial to maintaining a 
healthy brain (Wang et al., 2017). 
At physiologically level, A (4 kDa) a hydrophobic 39-43 amino acid peptide, exists not 
only in the brain, including neurons, astrocytes, microglia and cerebrospinal fluid (CSF), but as 
well as in periphery regions, organs and tissues, such as adrenal gland, kidney, heart, liver, 
pancreas, spleen, muscles and various blood and endothelial cells (Pawlowski, Meuth and Duning, 
2017). A peptides are the main compounds of SPs and derives from the proteolytic cleavage of a 
larger glycoprotein named APP.  
APP is an integral membrane protein, synthesized in the endoplasmic reticulum (ER), 
transported to the Golgi complex, and then glycosylated and further maturated (Toh et al., 2017). 
After, transported to the plasma membrane, mature APP, best known as the precursor molecule is 
cut by two membrane-bound endoprotease, -secretase and -secretase to produce A residue 
peptide (Haass and Selkoe, 1993). Mutations in the human APP gene cause the development of 
amyloid plaques, seen especially in early-onset AD pathology. These mutations related to APP 
gene are close to the -secretase site and can increase the AA ratio. Also, other mutations 
can occur in the genes PSEN1 and PSEN2 (Chen et al., 2017). 
Accordingly, there are different A species, but the two major isoforms of A peptide in 
human brain are A1-40 (80-90%) and A1-42 (5-10%), differing from each other by two amino 
acids. The slightly longer forms of Aβ peptide, in particular Aβ42 are more hydrophobic and 
fibrillogenic, and the main species accumulated in the brain (Murphy and Levine III, 2010). 
Besides that, A monomers aggregate into different forms of assemblies, such as oligomers, 
protofibrils and amyloid fibrils. These particular A forms may be involved in neurodegeneration 
events at different stages of AD condition. In fact, A aggregation in the brain, ultimately ends 
with the formation of insoluble protein fibrils, as a part of the components of amyloid plaques. 
Evidences suggest that neurotoxic species are named as soluble oligomers or protofibrils of A 
present on or off deposition pathways, leading to fibril formation (Dubnovitsky et al., 2013). 
A was first isolated as the principal component of amyloid deposits in the brain and in 
cerebrovasculature from DS and AD patients, playing a key role in the pathogenesis of AD 
condition (Murphy and Levine III, 2010).  
Usually, A levels in both b r a i n  an d  peripheral tissues are known to be lower in 
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cognitively normal elderly individuals, comparing with AD patients (Wang et al., 2017). A has 
been described in various organelles connected with degradative pathways linked to lysosome 
compartment, including endosomes (Cataldo et al., 2004), autophagic vesicles (AVs) (Yu et 
al., 2004), late endosomes (LEs) or multivesicular bodies (MVBs) (Takahashi et al., 2002) and 
lysosomes itself. Therefore, Aβ deposition may be the primary event, that occurs in SPs 
formation (Castellani, Rolston and Smith, 2010).  
The A production levels is balanced by the carrier- and receptor-mediated transport across 
the BBB by microglial cells and astrocytes. Moreover, the concentration of soluble A in the CNS, 
central for the formation of protofibrils and vascular aggregated A forms, is influenced by A 
active transport exchange through BBB (Wilhelmus, De Waal and Verbeek, 2007).  
This balance of A levels is acerbated in AD brains, resulting in an extensive depositation 
and aggregation of Aβ peptides. Furthermore, Aβ aggregation relates to generation of Aβ 
oligomers protofribils, the most toxic forms, responsible for initiating the degeneration process in 
neurons, and mature fibrils (Selkoe, 2000). These apparent toxic species — soluble Aβ oligomers 
— and their subsequent ability to cause neuronal injury, depend on the precision of an 
intramembranous proteolytic cleavage (Haass and Selkoe, 2007) .  
In vitro ,  some evidences support that aggregation may be linked to pathogenicity and Aβ 
protofibril may be the pathogenic species (Caughey and Lansbury, 2003). Other studies in vitro 
seem to demonstrate that Aβ42 aggregates into both amyloid fibrils and soluble intermediates 
much more rapidly than does Aβ40 (Levites et al., 2006). 
On the other hand, some studies in vivo demonstrated that Aβ42 is the predominant form 
of Aβ that accumulates in the AD brain, essential for seeding Aβ deposition (Younkin, 1998; Fryer 
and Holtzman, 2005). Literally, Aβ40 accumulates in AD brain, but the extent of Aβ40 
accumulation relative to Aβ42 is highly variable and usually attributed to deposition of Aβ40 in 
cerebral vessels (Kim et al., 2007).  
These findings support that an excessive Aβ accumulation and aggregation can trigger a 
complex downstream cascade, implicated in the symptoms of AD pathology. Amyloid cascade 
hypothesis proposes that gradual accumulation, as well as aggregation of A peptide, can lead to a 
slow deadly cascade resulting in synaptic alterations, microglial and astrocytic activation, 
modifications of normal soluble Tau protein into oligomers and later into insoluble PHFs, and 
progressive neuronal loss (Hardy and Higgins, 1992). 
This deadly cascade culminates with cell death, and cognitive failure resulting in a 
progressive dementia connected with Aβ and Tau pathologies (Haass and Selkoe, 2007) (Figure 
1.3). 
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Amyloid Cascade Hypothesis 
 
 
 
Figure 1:3 - The amyloid or A cascade hypothesis. Gradual changes in the steady-state levels of A in the brain are thought to 
initiate the amyloid cascade. Adapted from Haass and Selkoe, 2007. 
 
1.5 Tau Protein 
 
Microtubules are very dynamic structures, from cytoskeleton, responsible for the 
development of cell processes, establishment of cell polarity and intracellular transport. Some 
specific proteins are associated with its stabilization, including the microtubule-associated proteins 
(MAPs)- MAP1A, MAP1B, MAP2 and Tau protein. MAPs are seen specifically in mature neurons 
Increase in total Aβ production; 
Increase in the Aβ42/ Aβ40 ratio; 
Reduced Aβ degradation/ clereance. 
Aβ42 oligomerization and 
deposition as diffuse plaques. 
Subtle effects of soluble Aβ42 oligomers on synapses. 
 
Inflammatory responses 
(microglia and astrocytic activation) and 
amyloid plaque formation. 
Progressive synaptic and neuronal injury. 
Aberrant oligomerization and hyperphosphorylation of Tau 
(changes of kinase and phosphatase activities). 
Dementia with plaques and tangles pathology. 
Widespread neuronal dysfunction and 
cell death associated with neurotransmitter deficits. 
Altered neuronal ionic homeostasis; 
oxidative injury. 
Missense mutations in APP, PSEN1 or PSEN2 genes. 
Tangles 
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and Tau protein is preferentially abundant in axons (Avila et al., 2004). However, recent data 
suggest that Tau might play also a physiological role in dendrites (Mietelska-Porowska et al., 
2014). 
Tau protein (50kDa) is a very hydrophilic, soluble and displays a “natively unfolded” 
structure, stabilizing microtubules in neurons (Mandelkow and Mandelkow, 2012). It can be 
phosphorylated at multiple sites, which some are responsible to regulate its microtubule-binding 
properties (Mandelkow and Mandelkow, 1998). Tau protein can be found in many animal species, 
including Caenorhabditis elegans, Drosophila, rodents, monkeys, bovines and humans. On the 
other hand, in human beings, Tau protein is present in neurons, as well as in glial cells, mainly in 
pathological circunstances, and in numerous peripheral tissues, such as heart, kidney, lung, muscle, 
pancreas, testis and in fibroblasts (Buée et al., 2000). 
Basically, Tau function depends on its phosphorylation state, where the incorporation of 
phosphate groups into Tau protein is determined by its conformation and by the balance between 
the activities of Tau kinases (responsible for phosphorylation state) and phosphatases (responsible 
for dephosphorylation state). The non-phosphorylated forms preferentially link to microtubules 
(Kolarova et al., 2012). 
Notably, during the development of fetal brain, normal phosphorylated Tau proteins seems 
to be substantially higher; however in the adult brain neurons are normally characterized by a 
lower Tau phosphorylation state (Ballatore, Lee and Trojanowski, 2007).  
As a fact, several pathogenic phenomena may contribute directly or indirectly to Tau protein 
loses its biological activity and as consequence the capacity to bind to microtubules. 
For example, hyperphosphorylation, misfolding and aggregation, such as imbalance in the 
activity levels or regulation of Tau kinases and phosphatases, Tau gene mutations and post-
translational modifications may contribute to abnormal Tau protein accumulation in brain. Tau 
protein is a highly soluble cytoplasmic protein that binds to tubulin during its polymerization into 
microtubules in neurons  (Jouanne, Rault and Voisin-Chiret, 2017). Normally, in pathological 
conditions Tau protein do not bind to microtubules, resulting in an increase of abnormal levels 
of free (unbound) Tau fraction. Additionally, in normal Tau protein, both amino terminal 
and the carboxyl terminal flanking regions to microtubule binding repeats, appear to inhibit its 
self-aggregation into filaments. 
In AD ailment, abnormal hyperphosphorylation events, such as the phosphorylation of the 
amino terminal and the carboxyl terminal flanking regions occur, resulting in the formation of 
tangles of PHFS. The NFTs are mostly constituted by bundles of PHFs in AD pathology (Ballatore, 
Lee and Trojanowski, 2007) (Figure 1.4). 
In addition, aggregated of Tau filaments cannot be degraded by host neurons and gradually 
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accumulate within the cytoplasm. 
Thus, four Tau-based therapeutic approaches have been proposed: inhibition of Tau 
hyperphosphorylation; inhibition of Tau aggregation; clearance of Tau and Tau pathology; and 
rescue of neuronal plasticity by stabilizing the microtubule network or promoting 
neuroregeneration (Iqbal, Liu and Gong, 2016). 
 
 
Figure 1:4 - Pathological aggregation of Tau. A schematic representation of the different stages of the formation of pathological 
Tau aggregates. a. Abnormal disengagement of Tau from the microtubules and a concomitant increase in the cytosolic 
concentration of Tau are likely to be the key events that lead to Tau-mediated neurodegeneration. Direct causes of abnormal 
disengagement of Tau from the microtubules, include an imbalance of Tau kinases and/or phosphatases, mutations of the Tau gene, 
covalent modification of Tau causing and/or promoting misfolding, and possibly other causes such as other post- translational 
modifications. b. Once Tau is unbound from microtubules it becomes more likely to be misfolded. This is thought to be a stochastic 
phenomenon that is more likely at higher cytosolic Tau concentrations. c. Early deposits of Tau, called ‘pretangles’, are not stained 
by Congo Red or Thioflavine T, indicating that these intermediate forms of aggregated Tau do not exhibit the pleated  sheet 
structure typically found in amyloid aggregates. d. A structural transition leads to this more organized aggregate and the eventual 
development of NFTs. e. Such transitions may be facilitated by heterogeneous interactions with membranous structures. Adapted 
from Ballatore, Lee and Trojanowski, 2007. 
 
1.6 Cellular Proteolysis 
 
A fine maintenance of proteome integrity is necessary for a proper balance of protein 
homeostasis, cell function and viability, cellular control between synthesis, organelle biogenesis, 
trafficking and degradation of proteins. All these are crucial for a good cellular development, 
differentiation, maintenance and cell survival in a changing extracellular environment (Moreira et 
al., 2010). Accordingly, cells have an elaborate enzymatic machinery, named molecular 
chaperones that bind non-native polypeptides and promote their folding to the native state in an 
ATP- dependent manner (McClellan et al., 2005). 
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Besides that, diverse cellular events can influence protein misfolding during cell life, such 
as stochastic fluctuations, stress conditions or just metabolic changes, which particularly happen 
during aging and cancer (Chen et al., 2011). Failure to eliminate misfolded proteins can result in 
potentially toxic aggregates, inactivating functional proteins and finally leading to a cell death. 
Usually, cells require a continuous recycling of their cytoplasm to create macromolecular 
building blocks and energy, both under physiological and stress conditions (Nikoletopoulou, 
Papandreou and Tavernarakis, 2015). However, protein aggregation is a continuously ongoing 
cellular process, where some cellular vital functions require the aggregation of specific proteins. 
In other cases, protein aggregates generate by numerous stressors are a prerequisite to develop 
many pathologies, including neurodegenerative diseases (Hayat, 2013). 
The two distinct proteolytic systems in eukaryotic cells responsible for the complete 
degradation of intracellular proteins and recycling pathways are the ubiquitin-proteasome system 
(UPS), important for the degradation of 80-90% of proteins (short-lived, abnormal, denatured or 
in general, damaged proteins) and the autophagy-lysosomal pathway, capable of degrading most 
long-lived proteins, aggregated proteins, as well as cellular organelles (Lilienbaum, 2013). 
Focusing on autophagy-lysosomal pathway, autophagy (from Ancient Greek autófagos, meaning 
“self- eating”) was first described morphologically over 50 years ago, as a constitutive homeostatic 
process conserved from yeast to mammals (Coutts and La Thangue, 2016). In autophagy pathway 
cellular components, such as damaged organelles, long-lived or aberrant proteins and superfluous 
or aged portions of cytoplasm, are engulfed by autophagosomes and recycled through the 
lysosomal component without compromising cellular functions and tissue homeostasis (Caballero 
and Coto-Montes, 2012). 
Under physiological conditions, autophagy bears several vital roles, including maintenance 
of the amino acid pool during starvation, preimplantation development (oocyte fertilization) and 
differentiation (erythrocytes, lymphocytes and adipocytes) (Ravikumar et al., 2010), as well as 
prevention of neurodegeneration, anti-aging, tumor suppression, clearance of intracellular 
microbes and homeostasis of innate and adaptive immunity system (Mizushima, Yoshimorim and 
Levine, 2010).  
At the first sight, autophagy appears to be active at a low basal levels in most of the cells in 
our body, reflecting its main role on regulate the turnover of long-lived proteins and eliminate 
damaged structures (Codogno and Meijer, 2005). This autophagy- dependent quality control is also 
crucial to restrict the production of ROS (Beau, Mehrpour and Codogno, 2011). 
Even so, in different circumstances, autophagy can be stimulated during pathological and 
physiological states by nutrient deprivation (Cardoso, 2015), both in cultured cells and in intact 
organisms, from yeast to mammals. Besides starvation, responsible for playing a cytoprotective 
CHAPTER 1 
12 
 
 
effect by blocking the induction of apoptosis upstream of mitochondrial phenomes (Boya et al., 
2005), autophagy can be induced by other physiological stress stimuli, such as low oxygen levels, 
or decreased energy supply, ER stress, high temperature, hormonal stimulation, pharmacological 
agents (rapamycin), innate stimulation signals, among others (Mizushima, Yoshimorim and 
Levine, 2010). Bergamini and colleagues (Bergamini et al., 2007) have suggested that autophagy 
can be stimulated by CR extending lifespan in rat (Beau, Mehrpour and Codogno, 2011), through 
activation of deacetylase Sirtuin1 (Wang, 2014).  
On the other hand, a malfunction of autophagy causes several human diseases, where 
autophagy may be dysregulated, including liver, muscle and infectious diseases, as well as cancer 
and neurodegenerative disorders (Levine and Kroemer, 2008). 
 
1.7 Autophagic-Lysosomal Pathway 
 
1.7.1 An Overview 
 
Based on the type of cargo delivery in mammalian cells, there are three main forms of 
autophagy: Macroautophagy, Microautophagy and Chaperone-Mediated Autophagy (CMA). 
a. Macroautophagy: Macroautophagy is a conserved intracellular degradation pathway 
mediated by the autophagosome, a double membrane-bound vesicle, that traffics substrates 
engulfing cytoplasmic proteins and organelles, including ribosomes, mitochondria, ER, 
part of nucleus and peroxisomes, for delivery to the lysosome compartment to be degraded 
(Mizushima, Yoshimori and Ohsumi, 2011). 
b. Microautophagy: A non-selective lysosomal degradative process, engulfing soluble 
intracellular substrates directly by invagination, protrusion or septation through the 
lysosomal membrane under nutrient depletion that are subsequently degraded by lysosomal 
proteases. Microautophagy is induced by nitrogen starvation in yeast and rapamycin, as 
occurs in macroautophagy (Hayat, 2013). 
c. Chaperone-Mediated Autophagy (CMA): A uniquely selective form of autophagy, where 
only proteins are selected through a recognition motif in their amino acid sequences 
(KFERQ). The proteins are target with a specific cytosolic member of chaperone protein 
family-heat-shock protein of 70 kDa (Hps70), the heat-shock cognate protein of 70 kDa 
(Hsc70) to the lysosomal membrane protein, lysosomal-associated membrane protein type 
2A (LAMP-2A) receptor and then delivered into lysosomes lumen for degradation by the 
hydrolases (Cuervo and Wong, 2014). Furthermore, CMA and macroautophagy can act in a 
sequential manner during starvation process, where macroautophagy is activated and, if the 
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starvation persists, cells switch from this bulk degradation to CMA, targeting non-essential 
proteins for degradation to obtain the amino acids required for the synthesis of essential 
proteins (Orenstein and Cuervo, 2010). 
 
1.7.2 Autophagosomes Biogenesis 
 
The process of mammalian macroautophagy (henceforth autophagy) is divided into six 
principal steps: initiation, nucleation, elongation, closure, maturation and degradation or extrusion 
(Kang et al., 2011; Kim and Lee, 2014) (Figure 1.5). 
 
1.7.2.1 Initiation 
 
The first step of autophagosome formation is characterized ultrastructurally by the 
surrounding and sequestration portions of cytoplasmic organelles and proteins at the phagophore 
assembly site (also known as the isolation of membrane) (Kaur and Debnath, 2015). While discrete 
regions of ER enriched in phosphatidylinositol-3-phosphate (PI3P), called omegasomes (due to 
their  shape), may serve as the nucleation for the formation of autophagosomes in mammalian 
cells (Roberts and Ktistakis, 2013); many other evidences support that to create the membrane, 
which contribute to phagophore formation and elongation, different potential sources are 
requested: the Golgi complex, ER, ER-Golgi intermediate compartment, recycling endosomes, 
mitochondria and the plasma membrane (Rubinsztein, Bento and Deretic, 2015). 
The coordination of the membrane rearrangements that enhance autophagosome 
development, and their subsequent delivery to the lysosomal compartment, is stimulated by 
multiple autophagy- related (Atg) proteins. Several ATG genes, more than 30, have been identified 
in yeast genetic screenings. Most of these genes are conserved in humans and have orthologues in 
higher eukaryotes. The molecular composition of the autophagy-related 1 (Atg1), a 
serine/threonine kinase, complex appears to differ between yeast and mammals (Hosokawa et al., 
2009). 
In 2007, two mammalian homologues of Atg1 were discovered to be involved in autophagy, 
uncoordinated (UNC)-51-like kinase 1 and 2 (ULK1 and UKL2) complex. There is some 
redundancy between these two ULKs, with UKL1 having the main role. ULK1 was identified as 
the mammalian homolog of Caenorhabditis elegans UNC-51, being originally characterized as 
essential for neuronal axon guidance (Russell, Yuan and Guan, 2014). 
Autophagy is initiated by the ULK complex, composed by autophagy-related 13 (Atg13), 
autophagy-related 101 (Atg101) and scaffold protein, focal adhesion kinase (FAK)-family 
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interacting protein of 200 kDa (FIP200) or autophagy-related 17 (Atg17) (Mcknight, Mizushima 
and Yue, 2012).  
Basically, there are some autophagy inducers (cellular stress signals), including lowered 
concentrations of specific amino acids, growth factors or ATP, hypoxia, certain types of protein 
aggregates, ER stress and inhibition of mammalian target of rapamycin 1 (mTOR1), responsible 
for activating ULK complex, and then essential for autophagosome formation.  
Under nutrient-rich conditions ULK complex interacts directly with mTOR, however, during 
nutrient deprivation ULK complex dissociates from mTOR, being recruited to the site of 
autophagosome composition. This physically disengagement from mTOR, a series of 
phosphorylation/ dephosphorylation events involving UKL1, Atg13 and FIP200 ensures, that the 
complex achives at the autophagosome formation site is competent for the downstream steps 
(Nixon, 2013; Roberts and Ktistakis, 2013). 
Further, adenosine monophosphate (AMP)-activated protein kinase (AMPK) has been 
reported to play a role in the regulation of ULK during autophagy. In fact, various subunits AMPK 
complex may directly interact with the ULK1 network and phosphorylates different sites essential 
for ULK activation. 
 Although, AMPK and the mammalian rapamycin-sensitive mTOR complex 1 (mTORC1) 
can oppositely regulate ULK1/ULK2 kinase activity by direct phosphorylation (Alers et al., 2012). 
Under these circunstances, a dephosphorylation of UKL1/UKL2 occurs, and the UKL complex 
comprising UKL1, Atg13, Atg101 and FIP200 dissociate from mTORC1. Then, UKL1 is rendered 
enzymatically active and phosphorylates Atg13 and FIP200, leading to subsequent localization of 
the activated ULK network to the phagophore, beginning the process of autophagy (Kim and Lee, 
2014). 
Additionally, FIP200 also known as Retinoblastoma 1- Inducible Coiled-Coil 1 (RBCC1) is 
a multifunctional protein that has several interaction partners and regulates numerous cellular 
processes, such as cell growth, proliferation, cell spreading, and migration and it has been proposed 
to be a functional orthologue of yeast autophagy-related 17 (Atg17). FIP200 promotes ULK1 
kinase activity, translocate to the pre-autophagosomal membrane after starvation, occurs 
autophagosome induction and its role is extremely important for the stability and phosphorylation 
of ULK1 (Alers et al., 2012). 
On the other hand, Atg101, is a protein conserved in various eukaryotes, important for the 
stability and basal phosphorylation of Atg13 and UKL1 (Hosokawa et al., 2009). However, under 
nutrient rich conditions, the ULK complex interacts with mTORC1 and remains inactivated by 
mTORC1-mediated phosphorylation of ULK1/ULK2. 
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1.7.2.2Vesicle Nucleation 
 
The first step of autophagosome formation, autophagosome nucleation requires Beclin-1 
protein or autophagy-related 6 (Atg6). At this nucleation stage, the activated ULK kinase complex 
targets, a class III phosphatidylinositol 3- kinase (PI3K) containing, a vesicular protein sorting 34 
(Vps34), p150 a mammalian homolog of yeast vesicular protein sorting 15 (Vps15) and autophagy-
related 14 (Atg14)-like (Atg14L) protein or Barkor (Funderburk, Wang and Yue, 2010). All of these 
elements are associated with Beclin-1 protein to generate the pre-autophagosomal structure (Wong 
et al., 2013). 
Various additional components of Beclin-1 complex are also needed such as Ultraviolet 
radiation resistance-associated gene (UVRAG) and Beclin-1-regulated autophagy (AMBRA1), 
necessary to influence its functions and responsible for the induction of autophagy network (Liang 
et al., 2008). 
UVRAG is known to regulate autophagosome formation, binding to Beclin-1 during 
autophagy pathway. The B-cell lymphoma-2 (Bcl-2)- associated x (Bax)-interacting factor 1 (Bif1) 
interacts with Beclin-1 complex through UVRAG protein, and positively regulates autophagy and 
suppress tumorigenesis (Takahashi et al., 2007). 
Besides that, AMBRA1 is a positive regulator of Beclin-1-dependent autophagy and 
regulates the development of the nervous system.  
Furthermore, recruitment of other proteins required for the autophagosome formation, 
including WD-repeat domain phosphoinositide-interacting protein (WIPI) and double FYVE 
domain-containing protein 1 (DFCP1), both PI3P effectors, localized in ER and Golgi apparatus 
membranes, and though to help to drive progression of the omegasome to the isolation membrane 
(Axe et al., 2008).  
Another protein essential for the initiation of autophagy is autophagy-related 9 (Atg9), 
recruited to the autophagosome formation site. This protein is localized at the trans-Golgi network 
(TGN) and LEs, and during autophagy trafficked to endosomal membranes. Atg9 is involved in 
the early stages of autophagosome formation, leading to autophagosome expansion (Coutts and 
La Thangue, 2016). 
 
1.7.2.3 Vesicle Elongation 
 
The expansion of the isolation membrane is basically the simultaneous elongation and 
nucleation of little cistern. There are two ubiquitin-like complexes, involved in autophagosome 
elongation and maturation. The first ubiquitin-conjugation system, the autophagy-related 16-like 
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(Atg16L) complex is combined with the autophagy-related 12 (Atg 12) protein, and autophagy-
related 5 (Atg5) protein, essential for the formation of pre-autophagosomes, controlling autophagy 
pathway (Pyo, Nah and Jung, 2012). 
Atg12 is a 186 amino acid protein conjugated to Atg5 protein in a reaction that requires 
autophagy-related 7 (Atg7) protein, ubiquitin-activating-enzyme (E1)-like and autophagy-related 
10 (Atg10) protein, ubiquitin-conjugating-enzyme (E2)-like (Mizushima et al., 1998). Atg12-Atg5 
conjugate interacts non-covalently with Atg16L protein, ubiquitin-activating-enzyme (E3)-like to 
form Atg12-Atg5-Atg16L complex (Mizushima et al., 2004). 
The second ubiquitination-like protein conjugation system involves the lipidation of 
microtubule- associated protein 1A/1B-light chain 3 (LC3) or also autophagy-related 8 (Atg8).  
Autophagy-related 4 (Atg4) protein cleaves pro-LC3 to form cytosolic LC3I, which is 
covalently conjugated to phosphatidylethanolamine (PE), via autophagy-related 3 (Atg3)-
autophagy-related 7 (Atg7) and Atg 5-12 to form membrane associated LC3II (Mizushima et al., 
2004). This allows the association of LC3II with the autophagosome, where it remains bound until 
it is recycled during lysosomal degradation (Coutts and La Thangue, 2016). 
Atg5-Atg12 conjugate seems to modulate LC3I conjugation to PE by acting in an E3-like 
fashion manner (Hanada et al., 2007), and the Atg5-Atg12-Atg16L complex, determines the sites 
of LC3 lipidation. In this way, LC3 is specifically targeted to Atg5-Atg12-associated membranes, 
that expanded phagophores.  
Besides that, Atg5-Atg12 conjugate is lost upon completion of autophagosome formation, 
and LC3II remains associated with autophagosomes even after fusion with lysosomes, then LC3II 
on the cytosolic face of autolysosomes may be dilapidated and recycled to LC3I.  
Conjugated LC3 is a substrate for Atg4, which dilapidates LC3II, removing it from the 
membrane. Furthermore, the production of ROS; specifically, hydrogen peroxide (H2O2), during 
starvation results in oxidation and inactivation of Atg4 protein. This inhibits LC3II dilapidation 
and might promote autophagosome formation (Scherz-Shouval et al., 2007). LC3II is the only 
known protein that specifically associates with autophagosomes and not with other vesicular 
structures. 
Therefore, LC3I levels correlate with autophagic vacuole numbers, that can also be assessed 
by scoring LC3-positive vesicle numbers (Kabeya et al., 2000). LC3II can mediate membrane 
tethering and hemifusion, and these functions might be crucial for the expansion of autophagosome 
membranes. These data also raise the possibility that LC3 assists the final fusion of the pre-
autophagosomal double-membrane ‘cups’ into fused vesicles (Nakatogawa, Ichimura and Ohsumi, 
2007).  
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1.7.2.4Autophagosome maturation and fusion 
 
Autophagosomes form randomly in the cytoplasm, and once formed, autophagosomes 
traffick along microtubules in a dynein-dependent manner to lysosomes, which are clustered 
around the microtubule-organizing center (MTOC), located in the peri-nuclear region of the cell. 
There, autophagosomes tether, dock and fuse with lysosomes, and the contents of the two 
vesicles are released and mixed, generating a now mature autolysosome. The details of this aspect 
of mammalian autophagy are still unclear. However, the soluble N-ethylmaleimide-sensitive factor 
activating protein receptor (SNARE) proteins have been characterized and are involved in yeast 
autophagosome-vacuole fusion (Reggiori and Ungermann, 2017). 
In the route of fusion with lysosomes, autophagosomes can fuse with endosomes to form 
amphisomes. It is currently not clear whether amphisome formation is a prerequisite for 
autophagosome-lysosome fusion. Reduced activity of some endosomal sorting complex required 
for transport (ESCRT) proteins disrupts autophagosome-lysosome fusion, resulting in the 
accumulation of autophagosomes (Skibinski et al., 2005; Kim and Lee, 2014) (Figure 1.5). 
 
Figure 1:5 – Scheme of Autophagy-lysosomal pathway. Autophagy is regulated by multiple signalling pathways. Autophagic 
stimuli, including nutrient deprivation, or low energy, activate the ULK1/2 complex, which leads to increased activity of the Beclin-
1–Vps34 complex through phosphorylation of Beclin-1. PI3P produced by Vps34 recruits effector proteins, such as DFCP1 and 
WIPI, to promote autophagosome formation. Elongation of the autophagosome is mediated by two conjugated systems comprising 
Atg12– Atg5–Atg16L and LC3–PE. After formation of complete autophagic vesicles, the mature autophagosome becomes fused 
with a lysosome to create an autolysosome, where sequestered molecules and organelles are degraded (Filipe, 2018). 
CHAPTER 1 
18 
 
 
1.7.2.5 Lysosomal Pathway 
 
1.7.2.5.1 The Lysosome 
 
“Lysosome” term was originally coined by Christian de Duve (de Duve et al., 1955) to 
describe a newly discovered organelle, that housed a pool of soluble hydrolases, capable of 
degrading proteins, nucleic acids, carbohydrates, lipids and cellular debris (Lim and Zoncu, 2016). 
Firstly, characterized as granules, and long considered as “suicide bags”, lysosomes are catabolic 
membrane-bound organelles, the hub for proteostasis, present in all eukaryotic cells. Still, their 
size, shape, number and function differ greatly depending on species, cell type and context. These 
dynamic organelles function at the end of the endocytic, autophagic and phagocytic pathways 
(Wartosch, Bright and Luzio, 2015). In fact, lysosomal network, a degradation center and amino-
acid recycling within lysosomes, is responsible to degrade complex biological molecules (e.g., 
proteins and lipids) into simpler components (e.g., amino acids and free fatty acids), being recycled 
to the cytosol and reused either as a source of energy or as building blocks for the biosynthesis of 
new molecules (Fraldi et al., 2016). 
Lysosome, the incinerator of the cell, is a crucial regulator for cellular homeostasis events 
and can receive its substrates by multiple routes. In general, extracellular or cell surface cargos are 
delivered to lysosome through the endocytic pathway and the digestion of the intracellular 
components, occurs via a self-catabolic process known as autophagy (Saftig and Klumperman, 
2009). 
Lysosomes interact with LEs, also known as MVBs by direct fusion or ‘kiss-and-run’ events, 
and lysosomes fusing with endosomes form endolysosomes. Similialry, fusion of lysosomes with 
autophagosomes results in the formation of autolysosomes, and as well as fusion with phagosomes 
creates phagolysosomes (Wartosch, Bright and Luzio, 2015). 
The limiting membrane of the lysosome is composed of a single phospholipid bilayer, 
containing more than 100 transmembrane proteins, and the most abundant proteins the lysosomal 
membrane proteins (LAMPs) type 1 (LAMP-1) and type 2 (LAMP-2), are estimated to constitute 
80% of all proteins of the lysosome membrane protein content (Perera and Zoncu, 2016). One 
isoform of LAMP-2, the LAMP-2A is responsible to transport 30% of cytosolic proteins, which 
contain a KFERQ motif into lysosomes for degradation via CMA (Saftig, Schröder and Blanz, 
2010).  
 Once inside the lysosome, substrates are degraded by aproximadetly 60 resident acid 
hydrolases, including proteases, sulfatases, glycosidases, peptidases, phosphatases, lipases, and 
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nucleases.  
These proteins are synthesized at the rough endoplasmic reticulum (RER), traveling along the 
secretory pathway until reach the TGN, where are sorted and delivered to pre-lysosomal 
compartments. Additionally, mannose-6-phosphate (M6P) is the sorting signal for the majority, 
not all, of proteins designed to lysosomes. In fact, M6P groups have been found also in proteins 
with no lysosomal localization. Contrarily, proteins not bearing the M6P group can be targeted to 
the lysosome and proteins bearing the M6P group can be delivered to the lysosome independently 
of this group (mannose-6-phosphate receptor (MPR)-independent transport) (Castino and Isidoro, 
2008). 
Furthermore, these enzymes are turned to function optimally at the acidic pH 4.6-5.0 within 
the luminal environment of the lysosome, which is required for its internal hydrolytic activities, 
generated by the activity of lysosomal ion channels, ATP-dependent proton pumps (H+ ions), the 
vacuolar H+ ATPases (V-ATPases). Indeed, these proton pumps are essential to pH homeostasis 
in organelles. Proton gradient provides the driving force for the proton-coupled transport of 
metabolites, ions and soluble substrates into and out of the lysosomal lumen, necessary for a proper 
targeting of new synthesized lysosomal enzymes from the Golgi apparatus to the lysosome (Forgac, 
2007; Lim and Zoncu, 2016). 
Among the 60 resident lysosomal hydrolases, the best known of these enzymes are the 
cathepsin family of proteases (Appelqvist et al., 2013). Cathepsins are crucial to regulate different 
physiological processes, and show to be dysregulated in some diseases, thereby represent viable 
targets for therapeutic intervation (Kramer, Turk and Turk, 2017). 
A diverse human cathepsins have been identified, which can be subdivided into three distinct 
groups, according to the amino acid found in the active site, responsible for their catalytic activity; 
serine (A and G), cysteine (B, C, F, H, K, L, O, S, V, W and X), and aspartic cathepsins (D and E) 
(Zhang, Sheng and Qin, 2009).  
Cathepsin D (CatD) is one the most studied aspartic proteins, involved in diverse biological 
processes. CatD is synthesized in the RER as a preproenzyme (inactive zymogen). After removal 
of signal peptide, the proCatD (52 kDa) is targeted to endosomes to generate an active single-chain 
intermediate, active form (48 kDa), and then to the lysosomes to create the fully active mature 
protease composed by a heavy chain (34 kDa) and a light chain (14 kDa) (Domenico, Tramutola 
and Perluigi, 2016). It is widely known that the major function of CatD is its involvement in 
general protein degradation and turnover within the lysosome. Also, CatD appears be associated 
with different physiological functions and pathological scenarios, such as cancer, AD, 
atherosclerosis and inflammatory disorders (Pereira et al., 2015). 
Furthermore, during the last decades, more studies have demonstrated some abnormalities 
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of endo-lysosomal pathway at early and late stages of AD pathogenesis, related to lysosomal 
hydrolases (Cataldo et al., 1995). 
Lysosomal functions can be divided into three main types: degradation, secretion and 
signaling. As the last step of the conserved cellular process of autophagic pathway, lysosomal 
degradation is essential to preventing the accumulation of toxic or exhausted molecules and 
damaged organelles in the cell, as well known in neurodegenerative disorders. This particularly 
function is extremely important in neurons, nondividing cells, which are not capable of dilute 
cytosolic material during mitotic episodes (Settembre et al., 2013). Finally, cargoes are delivered 
to lysosomes basically through their fusion with endocytic vesicles and AVs, requiring the 
coordinated activity of three principal classes of proteins: (i) motor and adaptor protein complexes 
that regulate the vectorial movements of vesicles along microtubules (Ravikumar et al., 2005; 
Fraldi et al., 2016); (ii) membrane-associated RAB GTPases, such as Rab7, which control 
organelle trafficking and fusion (Kümmel and Ungermann, 2014) and (iii) lysosomal membrane 
proteins, LAMPs (Eitan et al., 2016). 
 
1.8 The Role of Autophagy in the Brain 
 
Brain is the most complex organ of human body, a temporal and spatially multiscale 
structure, responsible for many different purposes, including cognition, emotion, circadian 
behaviors and autonomic functions (Satoh, Imai and Guarente, 2017). It communicates with each 
part of the body through a network of interconnected neurons, the nervous system. During of aging 
process some alterations occurs in the brain, including homeostasis changes, cognitive skills 
failure and the risk to develop dementia or neurodegenerative disorders increases exponentially 
(Przedborski et al., 2008). The most widely noted cognitive adjustment relate to the process of 
aging is memory, especially episodic memory of hippocampus in medial temporal lobe region, a 
characteristic of the memory loss, typically seen in AD pathology (Peters, 2006). These events 
may exacerbate some negative effects, such as decrease production of new cells, low levels of 
neurogenesis, as well increase cellular damage, neuroinflammation, BBB disruption, reduced 
synaptic densities, ROS production and mitochondrial dysfunction (Camandola and Mattson, 
2017), autophagy and lysosomal pathways impairment (Carmona-Gutierrez et al., 2016). As a 
sequel, such events may result in neuronal dysfunction and neuronal cell death, which are seen in 
neurodegenerative disorders.  
Neurons are highly differentiated structures for intercellular communication with soma, 
dendrites, axons and synapses. As postmitotic cells, do not replicate in general and, it is believed 
that neurons have permanently blocked their capacity to proliferate, when differentiated, being 
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typically found in a quiescent state in the adult nervous system (Frade and Ovejero-Benito, 2015). 
For this reason, neurons have a predisposition for the accumulation of toxic proteins and damaged 
organelles inside of them, that could be diluted during cell division in replicating cells (Son et al., 
2012). Cell cycle reactivation in adult neurons is an early hallmark of neurodegeneration and CNS 
injury. 
Also, it has been reported that a specific disruption of autophagy in neuronal cells, results in 
neurodegeneration, reflecting a deficiency of basal autophagy levels in the mouse brain (knockout 
of either Atg5 or Atg7), which leads to an accumulation of ubiquitinated protein aggregates (Lenk 
et al., 1992). 
Autophagy activity is maintained at a low level in normal brain. Therefore, is essential for a 
normal function of the nervous system, playing a pivotal role in neuronal homeostasis during 
development, guarantee the shaping and function of the nervous system. Homeostasis in neurons 
include a vast synthesis and anterograde axonal transport of proteins, which must be balanced by 
a similar rate of retrograde transport and clearance by autophagy network (Kundu and Thompson, 
2008). 
In neurons is vital a constitutive active and highly efficient basal autophagic activity, 
characterized by particularly high levels of both ATP demand and protein synthesis (Lumkwana et 
al., 2017), maintaining the cell clean, and playing a neuroprotective role in synaptic neuronal 
plasticity anti-inflammatory function in glia cells, oligodendrocyte development, and myelination 
process (Martinez-Vicente, 2015; Nah, Yuan and Jung, 2015). 
Genetic studies have firmly established that the loss of basal autophagy by either deletion of 
ATG gene or inhibition of autophagic clearance in neurons originated disruption of axonal 
transport of vesicles containing substrates degraded in lysosomes and axonal swelling, leading to 
axonal dystrophy (Lee, 2012). 
 However, autophagy can play also a deleterious role, promoting neuronal damage and loss. 
For example, inhibition of autophagy during excitotoxicity stress can be protective and potentially 
promote recovery. This dichotomy suggests that the impact of autophagy can be influenced not 
only by neuronal subtype, but by the neuron’s age. Moreover, the yet unknown contribution of 
glial autophagy may also be a key factor in how autophagy affects neural health (Yamamoto and 
Yue, 2014). Evidences of an impairment in autophagy network have been reported in different 
neurological disorders such as in AD, where is noted to occur an abnormal amount of 
autophagosomes in the affected neurons (Wong and Cuervo, 2010). 
Basically, a failure of any molecule involved in autophagic process may lead to 
neurodegeneration. Additionally, the abnormal accumulation of autophagosomes in neurons 
imprint the first sign of deficits in autophagy pathway. Besides that, autophagosomes and their 
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presence in cells depends on both rate of formation and rate of clearance by lysosomal network 
degradation.  
An example of this, is the observation in cultured primary neurons that blocking 
autophagosome clearance by inhibiting cathepsins causes rapid AVs accumulation without altering 
autophagy induction (Bolanda et al., 2008). The impairment of later digestive steps in the 
autophagy pathway, as well as, a slow rate of autophagosome formation combined with 
insufficient lysosomal fusion and digestion, reflects a deficiency in autophagy network in 
neurodegenerative disorders (Viscomi et al., 2017). 
Other evidences about the critical role of autophagy in the basal turnover of diffuse cytosolic 
proteins in neurons, suggest that large inclusion bodies themselves might not be pathogenic, but 
mutant proteins present diffusely in the cytosol could be the primary source of toxicity. For this 
reason, it is possible that  autophagosomes can selectively recognize abnormal soluble proteins or 
micro-aggregates on the membrane surface (Mizushima and Klionsky, 2007). However, the exact 
mechanisms that leading to this autophagic dysfunction and how a dysfunctional autophagy may 
lead to neuronal death is still not well understood. 
Summarizing, basal autophagy is extremely important for good manner function of neurons, 
playing a cytoprotective role, and preventing build up proteins aggregates, as well as damaged 
mitochondria (Murrow and Debnath, 2013). 
 
1.9 Autophagy in Neurodegenerative Disorders 
 
Some abnormal accumulation of Avs, including autophagosomes or autolysosomes has been 
described in affected neurons of brain, reflecting an autophagy network dysfunction in several 
neurodegenerative disorders such as AD, PD, Huntington’s Disease (HD), Amyotrophic Lateral 
Sclerosis (ALS), among others (Frake et al., 2015). 
Even some studies from post-mortem brains with these neurological disorders, have reported 
how autophagy may contribute to neurodegeneration. For this reason, in a nearly future autophagy 
system may be a potential therapeutic avenue for neurodegenerative maladies (Ciechanover and 
Kwon, 2015). 
 
1.9.1 Autophagy in AD 
 
Nowadays, some increasing evidences support that autophagy pathway dysfunction is 
implicated in AD pathogenesis. The first evidence that autophagic activity was associated with 
AD pathogenesis theory, came from the observation of AVs in biopsy specimens of neocortex 
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from brains of AD patients, where AVs proliferation is unexpected robust in dystrophic neurites, 
including grossly abnormal accumulations of immature forms of AVs (autophagosomes) (Nah, 
Yuan and Jung, 2015). Basically, AVs are uncommon in neurons of a healthy brain. The results 
from Nixon and colleagues proved that lysosomal system mobilization, what occurs in AD, is 
connected in somehow, with the induction of autophagy in affected neurons within neuritic 
processes, as synapses regions. This suggests that while autophagy may be induced in AD 
condition, AVs transport and maturation can be also impaired in damaged neurons (Nixon et al., 
2005). 
Additionally, data already reported that the amount of AVs are much more present in 
neurodegenerative diseases brain than in health controls, indicating strongly evidences the failure 
maturation of autophagosome to autolysosome step (Guo et al., 2017). Even more, studies have 
identified abundant accumulation of bodies as early or late AVs, or autophagosomes and 
autophagolysosomes, which are intermediate structures of autophagy network (Funderburk, 
Marcellino and Yue, 2010). 
Also, depletion of key autophagy genes such as Atg5 and Atg7, that are essential for 
autophagosome evolution, may lead to neurodegeneration in mouse CNS (Komatsu et al., 2006). 
On the other hand, Hara et al. (Hara et al., 2006) described in theirs studies that inclusions 
bodies, proteins aggregates, appeared in later phases of autophagy deficiency, implying that the 
primary role of autophagy process under normal conditions is the turnover of diffuse cytosolic 
proteins and not the direct elimination of inclusion bodies (Hara et al., 2006). 
All these data, support abnormalities in autophagy induction, as well as, in autophagosome 
formation, which in somehow contribute to AD pathogenesis. Besides, it is important to refer that 
a selective transport deficit, compromising in general autophagy-related compartments, have been 
described in mouse and cell models of AD pathology (Nixon and Yang, 2011). 
For example, axonal transport is focally interrupted by nerve ligation or toxic agents, which 
often accompanies neurodegeneration. In addition, this axonal disrupted transport has been 
described in live-imaging studies of cortical neurons, when lysosomal proteolysis is inhibited, 
leading to an axonal dystrophy, characterized by a selective AVs accumulation, as believed to 
occur in AD condition (Sooyeon, Sato and Nixon, 2011). 
Although, a recent study has stablished that in contrast to degradative role of autophagy 
ending in lysosomal degradation already described, autophagy pathway may influence the 
secretion of A. Particularly in this study, Nilsson and colleagues hypothesizes (Nilsson et al., 
2013) that, autophagy may directly affect intracellular A accumulation and extracellular A 
plaque generation. Autophagosomes are sites of A formation that can fuse with endosomes at the 
late stage of autophagy pathway, and A-containing endosomes may potentially be the source of 
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A delivered to extracellular milieu. This releasement of A to extracellular space may be 
influenced by autophagy network as a general excretory mechanism for cellular waste, 
independent of the regulated secretory pathways as well-known (Nilsson et al., 2013). 
At the other sight, Beclin-1, a crucial key in autophagosome generation, has been shown to 
be transcriptionally suppressed in AD brains. Under pathogenic conditions, Caspase-3 as an 
essential component in apoptosis pathway, may cleave Beclin-1 protein, leading to autophagy 
disruption. The cleaved form of Beclin-1 is therefore regarded as a common in vitro marker for 
apoptosis in AD pathogenesis (Kang et al., 2011). Therefore, pharmacological targeting the 
induction of autophagy can have potential therapeutic benefits, reducing neurodegeneration in AD. 
At this regard, autophagic activity induction before the development of AD-like pathology 
can reduce the levels of soluble A and Tau proteins, whereas autophagic activity induction after 
the formation of mature plaques and tangles installed, may not have effect on AD-like pathology 
or cognitive deficits (Viscomi et al., 2017). Thus, an accumulation of AVs is likely arising from 
impaired clearance rather than the induction of autophagy pathway itself, suggesting the 
modulation of late steps of autophagy as a possible therapeutic strategy for AD malady. 
 
1.10 Beclin-1 
 
Beclin-1, a coiled-coil protein was first identified as a direct interactor of the Bcl-2 protein 
in a yeast two-hybrid screen (Liang et al., 1998). Beclin-1, also named Atg6 is a highly conserved 
in eukaryotes and can restore starvation-induced autophagy in ATG6- disrupted yeast strains, 
regulating positively autophagic activity (Hayat, 2013).  
Atg6 has been well-characterized to play a crucial protective role in autophagy network, for 
reducing protein aggregates, also as a fundamental regulator of autophagy process in the nucleation 
of the autophagosomes, as well as for the maturation step of the pathway (Cao and Klionsky, 
2007). 
Recently, another member of Atg6/Beclin-1 family, Beclin-2 was discovered and 
demonstrated to bear an important role in two different lysosomal degradation pathways, essential 
for cellular homeostasis, autophagy and endolysosomal trafficking of G protein-coupled receptors 
(Kang et al., 2011). Nowadays, studies have described that Beclin-1 is a haploinsufficient tumor- 
suppressor gene that is either monoallelically deleted or display reduced expression in various 
cancers, such as human breast, ovarian and prostate cancer (Zhu and He, 2015). 
Moreover, Beclin-1 is involved in numerous biological processes, as well as in human 
conditions, including adaptation to stress, development, endocytosis, tumorigenesis, pathogen 
infection and neurodegeneration (Hayat, 2016). 
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Struturally, Beclin-1 is a 450-amino acid protein that contains three distinct functional 
domains: a Bcl-2 homology-3 (BH-3) motif at the N terminus (residues 114-123), a coiled-coil 
domain (CCD) in the center (residues 144-244) and an evolutionarily conserved domain (ECD), 
at C-terminal (residues 244-337), which allows multiple protein interactions (Fu, Cheng and Liu, 
2013).  
Bcl-2 directly bind the BH-3 domain of Beclin-1 and effectively counteract Beclin-1 
dependent autophagy. The anti-apoptotic role of Bcl-2 can suppress autophagy pathway. Even 
phosphorylation and ubiquitination events of Beclin-1 and Bcl-2 may either stabilize or dissociate 
the Beclin-1-Bcl-2 complex, leading to inhibition or initiation of autophagy pathway, respectively 
(Wirawan et al., 2012).  
The CCD domain is involved in heterodimerization with UVRAG, but can function 
independently to Beclin-1 (Sinha and Levine, 2008). Beclin-1 can interact with other proteins, 
such as Bif-1. Additionally, through its ECD and CCD, Beclin-1binds PI3K-III complex, which 
regulates autophagosome formation.  
Likewise, Beclin-1 contains a short leucine-rich amino acid sequence, a nuclear export signal 
(NES), located within the CCD domain (Zhu and He, 2015).  
The NES is responsible for the predominant cytoplasmic localization of Beclin-1, and within 
cytoplasmic structures Beclin-1 exists primarily to ER, mitochondria, TGN and perinuclear 
membrane (Kang et al., 2011; Fu, Cheng and Liu, 2013; Zhu and He, 2015). (Figure 1.6). 
 
 
Figure 1:6 - The structure of Beclin-1. Schematic representations of domains of human Beclin-1. Beclin-1 has a Bcl-2 homology-
3 (BH-3) motif at the N terminus (residues 114-123), a central coiled-coil domain (CCD) in the middle (residues 144-244) and an 
evolutionarily conserved domain (ECD), at C-terminal (residues 244-337). Adapted from Fu, Cheng and Liu, 2013. 
 
Beclin-1 is expressed in many human and mouse tissues, including in brain, heart, liver, 
spleen, ovary, among others (Liang et al., 1998). Beclin-1 protein is a part of a lipid kinase 
complex, imperative for autophagy pathway, involved in different scenarios, including tumor 
suppression, longevity, innate immunity, neuroprotection and cell death (Funderburk, Wang and 
Yue, 2010). Beyond autophagy, Beclin-1 functions are evident in other membrane-trafficking 
pathways, such as endocytic and phagosomal maturation. 
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Therefore, Beclin-1 is a central hub that regulates environmental stimuli with downstream 
physiological outputs, when different signaling path, as oncogenic/tumor- suppressive, immune, 
and stress-responsive signals converge on Beclin-1 to regulate autophagy network (Levine et al., 
2015). 
 
1.11 Beclin-1 and Neurodegenerative Disorders 
 
In mammalian adult brain, Beclin-1 is expressed in neurons and glia cell population, 
specially astrocytes from different regions, cerebral cortex, hippocampus and cerebellum (Erlich, 
Shohami and Pinkas-Kramarski, 2006). During of aging process, Beclin-1 levels decline, where at 
same time the levels of aggregate-prone proteins accumulate, and some collapsing effects at give 
point on the system of autophagic homeostasis may happen, leading to irreversible dysfunction 
and/or death of neurons. 
Besides, different studies have been observed a decreased of Beclin-1 levels aged brains in 
various neurodegenerative disorders, such as AD (Pickford et al., 2008), HD (Shibata et al., 2006) 
and Machado-Joseph (MJ) (Nascimento-Ferreira et al., 2011). 
 
1.11.1 The connection between Beclin-1 and AD 
 
Beclin-1 and its interacting proteins are important in aging and age-related 
neurodegenerative pathologies. It is been described that Beclin-1 levels decline with age in the 
human brain, confirming that decreased Beclin-1 levels lead to an impairment of autophagy 
activity and at the same time, autophagy decline role is probably an important factor contributing 
to aging (Morris et al., 2015). 
The first article, reporting the protective effects of an overexpressed levels of Beclin-1 in 
neurodegenerative diseases was published in 2008. Pickford et al. (Pickford et al., 2008) have been 
reported that endogenous protein levels of Beclin-1 were seen reduced in post-mortem brain 
samples of AD patients, specifically in gray matter. This overexpression of Beclin-1 levels was 
described to alleviate AD condition (Pickford et al., 2008). Additionally, in subjects with mild 
cognitive impairment (MCI) or severe AD, they found that both messenger ribonucleic acid 
(mRNA) and protein levels of Beclin-1 were reduced only in affected brain parts, such as the 
entorhinal cortex (Lee and Gao, 2008). Also, in the same study, authors demonstrated that in 
transgenic mice deficient in Beclin-1 protein, a disruption of autophagic pathway, increased 
neurodegeneration and A accumulation (Rohn et al., 2011).  
Besides, Beclin-1 levels were seen reduced in microglia from AD patients, reflecting a 
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reduced retromer trafficking, and suggesting deficits in receptor mediated A phagocytosis (Wang 
et al., 2018). Although, the mechanisms behind of this reduction are still not clear.  
Furthermore, an activation of autophagy or an overexpression of Beclin-1 levels may prevent 
neuronal cell death and may benefit clearance of toxic protein aggregates. It is also reported that 
both Beclin-1 and Vsp34 protein levels are reduced in AD tissue, reinforcing one more, a 
compromising initiation of autophagy pathway (Jaeger and Wyss-Coray, 2010). 
One hypothesis, that could explain the decline levels of Beclin-1 seen in AD malady is an 
impairment of autophagosome-lysosomal function, which may active a negative feedback loop, 
downregulating autophagy induction in response to abundant autophagosome numbers. This loop 
may be preventing an uncontrolled run-off activation of autophagy with potentially serious 
consequences for the cell (Jaeger et al., 2010). 
And may be an upregulation of Beclin-1 should compensate for this reduction instead of 
leading to an unphysiological excessive activation of autophagy but, since Beclin-1 function is 
tightly regulated by other proteins, such as Bcl-2, a permanent upregulation or overexpression 
should not lead to an excessive autophagy situation (Jaeger and Wyss-Coray, 2010). 
 
1.12 Sirtuins: a key in Neurodegenerative diseases 
 
1.12.1 The History of Sirtuins: A Family of Proteins 
 
1.12.1.1 The Basics 
 
The mammalian family of deacetylases of histones (HDACs) are involved in several 
biological processes and divided into four classes: class I- HDAC1, -2, -3, and - 8; class II- 
HDAC4, -5, -6, -7, -9 and -10; class III- Sirtuins; and class IV- HDAC11, based on sequence 
similarity and co-factor dependency (Yang and Seto, 2007). 
Class III HDACs, also known as Sirtuins (SIRTs), constitute a special family of proteins 
because of their requirement for nicotinamide adenine dinucleotide (NAD+) as a cofactor in their 
deacetylation reaction (Rothgiesser et al., 2010) and for being involved in regulating a variety of 
pathways, including aging and longevity in lower eukaryotes such as Drosophila melanogaster 
and Caenorhabditis elegans (Michishita et al., 2005). During the deacetylation process, 
nicotinamide (NAM) is cleaved from NAD+ and the acetyl group of the substrate is afterwards 
transferred to adenosine diphosphate (ADP) ribose, generating the novel metabolite 2’-O-acetyl-
ADP ribose (OAADPr) (Denu, 2003). 
The SIRTs family has high homology to the yeast silent information regulator 2 (Sir2) gene 
CHAPTER 1 
28 
 
 
and consists of seven isoforms in mammals (SIRT1-SIRT7), which vary in their subcellular 
localization, substrate specificity, enzymatic activity, targets and functions (Blander and Guarente, 
2004) (Table 1.1). 
 
1.12.1.2 SIRTs subcellular localization 
 
SIRTs are ubiquitously expressed, containing a conserved catalytic core domain comprised 
of approximately 275 amino acids. SIRTs regulate a diversity of cellular functions, including 
genome maintenance, longevity and metabolism, exhibiting a different pattern in their subcellular 
localization from nucleus to nucleolus, and from cytoplasm to mitochondria (Rothgiesser et al., 
2010; Cantó and Auwerx, 2012). 
SIRT1, the best characterized family member, is mainly located in the nucleus but also 
present in the cytosol. Under certain conditions, its nuclear export signal can shuttle from the 
nucleus to the cytosol, but the physiological relevance of this shuttling is still unclear (Houtkooper, 
Pirinen and Auwerx, 2012). 
SIRT2 is predominantly cytoplasmic, but has also been found in the nucleus, modulating cell 
cycle control- G2 phase to M phase transition of the cell cycle (Chang and Guarente, 2014). SIRT3 
(Ansari et al., 2017), SIRT4 (Anderson et al., 2017), and SIRT5 (Guedouari et al., 2017) are 
considered mitochondrial proteins. Both SIRT6 (Tasselli, Zheng and Chua, 2017) and SIRT7 
(Fukuda et al., 2018) are present in the nucleus. SIRT6 has essential roles in heterochromatin 
silencing and SIRT7 has been identified in the nucleolus, important to regulate RNA polymerase 
I transcription (Michan and Sinclair, 2007; Li et al., 2016). 
 
1.12.1.3 SIRTs enzymatic activity 
 
Enzymatic activity by SIRTs requires NAD+ as a co-substrate, distinguish them from the 
other classes of protein deacetylases. In addition, the concentration of each deacetylases is 
determined by the nutritional stated of the cell (Feldman, Dittenhafer-Reed and Denu, 2012). 
During this enzymatic reaction process catalyzed by SIRTs, NAD+
 
is converted to NAM, also 
named vitamin B3, the first product released, followed by deacetylated lysine and OAADPr (Cantó 
and Auwerx, 2012). Indeed, NAM at higher concentrations can non-competitively bind and thereby 
feedback-inhibit SIRTs activity (Houtkooper, Pirinen and Auwerx, 2012).  
Among the seven SIRTs, only SIRT1-3 display a robust deacetylase activity in vitro, whereas 
recent reports implicate SIRT5, a class III mitochondrial SIRT, as a protein desuccinylase and 
demalonylase  (Teng et al., 2015). SIRT2 possesses efficient demyristoylase activity. Moreover, 
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SIRT6-7 exhibit little or undetectable deacetylation activity in vitro. Although, SIRT4 and SIRT6 
were described as ADP-ribosyltransferases. Finally, SIRT6 exhibits three distinct enzymatic 
activities, deacetylase, ADP-ribosyltransferase and defatty-acylase (Gomes, Outeiro and Cavadas, 
2015). 
 
1.12.1.4  SIRTs function 
 
Different roles of SIRTs have been described in a great number of different conditions. 
SIRT1 is involved in a several physiological mechanisms and regulates numerous functions, which 
are going to be described in more detail later. 
Additionally, SIRT2 regulates cell cycle and is associated with various mitotic structures, 
such as the centrosome, mitotic spindle and midbody to ensure normal cell division. SIRT2 
overexpression occurs in the M phase of mitotic cycle (de Oliveira et al., 2012). SIRT2 is 
responsible for transcription under regulatory pathways that control oligodendrocytes 
differentiation and myelin expression (Zhu et al., 2012). Also, SIRT2 has been shown to 
deacetylate and activate FOXO3 a in response to oxidative stress (Gomes, Outeiro and Cavadas, 
2015). 
SIRT3 influences energy metabolism processes, including fatty acid -oxidation, respiratory 
chain, ketogenesis and tricarboxylic acid cycle by targeting the responsible enzymes. It also 
controls the flow of mitochondrial oxidative pathways and, ultimately, the rate of ROS (Ansari et 
al., 2017).  
SIRT4 has been shown to repress glutamate dehydrogenase activity and suppresses insulin 
secretion in mouse models. Moreover, SIRT5 can promote in liver the detoxification of ammonia 
by deacylating and activating carbamoyl phosphatase synthetase 1, the first and rate-limiting 
enzyme in the urea cycle (van de Ven, Santos and Haigis, 2017).  SIRT6 plays a role in genome 
integrity, metabolic regulation and controls flux of glycolysis  (Pan et al., 2011). 
Finally, SIRT7 is associated with active ribosomal ribonucleic acid (rRNA) genes, interacting with 
ribonucleic acid (RNA) polymerase I. Its overexpression increases rRNA transcription, whereas 
its down-regulation decreases rRNA transcription  (Yamamoto, Schoonjans and Auwerx, 2007). 
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Table 1-1 - SIRTs Subcellular Localization, Enzymatic Activity and Functions. 
 
SIRTs Class 
Subcellular 
Localization 
Enzymatic 
Activity 
Functions 
SIRT1 I Nucleus, Cytosol Deacetylation 
Chromatin structure 
Cell cycle Glucose metabolism 
Insulin secretion 
Neuroprotection Fatty acid oxidation 
SIRT2 I Cytosol, Nucleus 
Deacetylation, 
Demyristoylation 
Cell cycle control 
Oligodendroglia proliferation 
Oxidative stress 
SIRT3 I Mitochondria Deacetylation 
Metabolic regulation 
Oxidative stress 
Acetate metabolism 
Insulin secretion 
-oxidation 
SIRT4 II Mitochondria ADP-ribosylation Insulin secretion 
SIRT5 III Mitochondria 
Deacetylation 
Demalonylation 
Desuccinylation 
Urea cycle 
SIRT6 IV Nucleus 
Deacetylation 
ADP-ribosylation 
Defaty-acylase 
Glucose homeostasis 
Telomeric function 
DNA repair 
SIRT7 IV Nucleolus Deacetylation RNA pol I transcription 
 
Summarizing, SIRTs are engaged in extremely complex cellular and physiological 
processes: proliferation, differentiation, stress response, genome stability, cell survival, 
metabolism and energy homeostasis and aging process (Table 1.1). Due to the multifaceted and 
ubiquitous nature of these class of proteins, in particularly of SIRT1, studies have described its 
role in chronic inflammatory diseases, diabetes mellitus type II, cardiovascular, neurodegenerative 
and kidney diseases (Michan and Sinclair, 2007). Therefore, it is believed that SIRTs, in a near 
future, will play a part in new therapeutics applicable to multiple pathophysiological states. 
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1.12.2  SIRT1: Biological Function and Targets 
 
SIRT1, the mammalian ortholog most highly related to Sir2 is by far the best characterized 
family member of SIRTs. SIRT1 is involved in a wide range of cellular biological pathways, such 
as DNA damage repair, inflammation process, mitochondrial homeostasis, insulin secretion, stress 
response, apoptosis, genome stability, among others (Polito, Biella and Albani, 2017). SIRT1 is 
highly expressed in a wide range of tissues and organs including heart, liver, muscle, pancreas, 
brain and adipose tissue mice (Nogueiras et al., 2012). (Figure 1.7). Moreover, SIRT1 has been 
shown to reduce age associated physiological changes in mice (Guarente, 2007). 
Several lines of evidence, indicate numerous neuroprotective functions that SIRT1 plays, 
such as anti-oxidant and anti-inflammatory response, anti-apoptosis, regulation of insulin, gene 
transcription, autophagy and mitochondrial biogenesis (Braidy et al., 2012). In fact, SIRT1 protein 
has been reported to play also, a role in a variety of pathophysiological processes of metabolic 
diseases, neurodegenerative disorders, cancer and aging (Zschoernig and Mahlknecht, 2008). 
Therefore, because of SIRT1’s ability to deacetylate both histones and non-histone 
substrates, to promote directly an activation or inhibition of transcriptional factors and modify their 
interaction profiles, SIRT1 became an important target to innovative molecular therapy strategies. 
First, hepatic metabolic derangements are key components in the development of fatty liver, 
insulin resistance, and atherosclerosis. SIRT1 plays an important regulator of energy homeostasis 
in response to nutrient availability. SIRT1 deacetylase is expressed in the pancreatic β-cells, as 
well as glucagon-producing α-cells. In β-cells, SIRT1 enhances insulin secretion by suppressing 
the expression of uncoupling protein 2 (UCP2). Additionally, SIRT1 protein appears to have a 
protective effect against glucose-induced cytotoxic in pancreatic β-cells, causing β-cell 
degeneration, seen in diabetic patients with chronically high plasma glucose levels. These 
cytotoxic effects of increased glucose concentrations are associated to elevated mitochondrial 
oxidation rates, leading to an increase of ROS production (Anastasiou and Krek, 2006). 
Another site of SIRT1 deacetylase protein function relates to genes that control mammalian 
energy and nutrient homeostasis. In liver, SIRT1 is known to control gluconeogenic activity by 
modulation of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) 
(Canto and Auwerx, 2009). Finkel’s group identified the functional interaction and deacetylation 
of PGC-1α and SIRT1 (Nemoto, Fergusson and Finkel, 2005). 
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Other studies have been focus on the important role of hepatic SIRT1 deacetylase as a 
regulator of lipid homeostasis in response to nutrient availability by positively regulating 
peroxisome proliferators-activated receptor a alpha (PPARα), a nuclear receptor, responsible for 
mediating the adaptive response to fasting and starvation, whereas pharmacological activation of 
SIRT1 can prevent of obesity associated metabolic diseases (Purushotham et al., 2009). However, 
scientists have been study the effect of SIRT1 also in neurodegeneration, once  its protective role 
as been shown in several models of neurodegenerative disorders, such as AD pathology. 
Additionally, another target of SIRT1 is against chronic inflammatory effects in diverse 
tissues and cells models by controlling the acetylation of nuclear factor kappa Beta (NF-ĸB), a 
transcription signaling pathway involved in the innate immune response, by downregulating its 
transcriptional activity (Rahman & Islam 2011). It has been reported that SIRT1 protein is elevate 
in cancer, such as prostate and primary colon cancer, acute myeloid leukemia and in skin cancers, 
including squamous cell carcinoma, basal cell carcinoma and actinic keratosis (Zilfou and Lowe, 
2009; Rahman and Islam, 2011). Another family of transcription factors that are deacetylated by 
SIRT1, the Forkhead-O-box (FOXO), play an important key as regulator of lipid metabolism, 
stress resistance and apoptosis. For instead, FOXO3 is an important factor on upregulation of 
genes, that are involved in the apoptosis-induced stress, whereas FOXO1 plays a different role on 
regulating the expression of metabolic genes (Giannakou and Partridge, 2004). 
Therefore, SIRT1 activity involving the deacetylation of FOXO3 and FOXO1 occurs in 
situations of oxidative and energy stress, and fasting. Besides this SIRT1-mediated FOXO 
deacetylation can also activate autophagy pathway. Recently, some studies have shown that 
adipose tissue is an important organ in lifespan, where SIRT1 represses peroxisome proliferator- 
activated receptors gamma (PPARγ) inhibiting lipid accumulation in adipocytes. 
For all these functions that SIRT1 deacetylase show in so many physiological and 
pathological conditions, scientists have been focus on the effects of SIRT1 in neurodegeneration 
because of its protective role in several models of neurodegenerative disorders, such as AD 
pathology. 
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Figure 1:7 - Biological functions of SIRT1 protein in different physiological and pathological conditions. Adapted from 
(Nogueiras et al. 2012) 
 
1.12.3  The Role of SIRT1 in CNS 
 
1.12.3.1 Brain- Can SIRT1 protect the brain? 
 
Several SIRTs are expressed in the mammalian brain, playing different roles on diverse brain 
functions and respond in dissimilar ways to stress and toxicity (Satoh and Imai, 2014). The best-
characterized SIRTs family member, SIRT1 is ubiquitously present in areas of the brain, especially 
susceptible to age-related neurodegenerative states, including the prefrontal cortex, hippocampus 
and basal ganglia (Kelly, 2010). Furthermore, SIRT1 is also expressed in metabolic centers of the 
brain, such as the hypothalamic arcuate, ventromedial, dorsomedial, and paraventricular nuclei 
(Paraíso, Mendes and Santos, 2013). Also, it is involved in mechanisms of cellular protection 
against oxidative stress in different conditions from aging to neurodegeneration processes. For this 
reason, data have described that SIRT1 participates in the maintenance of the brain integrity, 
regulating activities like oxidative stress, neuronal differentiation and neurogenesis (Ramadori and 
Coppari, 2011; Herskovits and Guarente, 2014). 
 
 
CHAPTER 1 
34 
 
 
1.12.3.2 SIRT1: Role in Neurogenesis 
 
Neurogenesis is the process of producing new neurons from neural stem cells (NSCs). In 
most brain regions, this process is restricted to a limited period during development, and ends shortly 
after birth. Although, neurogenesis is observed into the postnatal period and throughout adulthood 
(Götz and Huttner, 2005), a multistage process regulated by a delicate balance between 
undifferentiated proliferative neural precursors cells and differentiated neuronal progeny. There are 
two evolutionarily conserved neurogenic niches in the adult mammalian brain, the subventricular 
zone (SVZ) (Ming and Song, 2011), which lines the lateral wall of the lateral ventricle and the 
subgranular zone (SGZ), that lies within the dentate gyrus of the hippocampus. Numerous 
transcription factors regulators, associated in NSCs selfrenewal and fate regulation, have been 
described for both neurogenic niches (Saharan, Jhaveri and Bartlett, 2013). 
The link between SIRT1 and neurogenesis came from the finding that it can mediate cellular 
responses to changes in redox state in several different cell types (Libert, Cohen and Guarente, 
2008). As an example of these diversity of cell types, Prozorovski et al.  (Prozorovski et al., 2008) 
showed that SIRT1 is directed involved in neural progenitors, under oxidative conditions both in 
vitro and in vivo, by promoting an astroglial lineage (Prozorovski et al., 2008). Also, SIRT1 has 
been shown to regulate pluripotency and differentiation genes in human embryonic stem cells. 
Recently, data have reported that SIRT1 ubiquitously expression is linked with high levels of 
expression in the developing mouse CNS, adult mouse and human brain (Herskovits and Guarente, 
2014). For this reason, some studies have stated that the inhibition or silencing of SIRT1 can 
promote or alter neuronal differentiation. In the adult brain regions, expression of SIRT1 is more 
noticeable in neurons of the hippocampus and hypothalamus, with a more nuclear localization. 
The hypothalamus region is an important area of the brain, responsible to control human 
physiology, including regulation of body temperature, hunger/satiety, circadian rhythms and on 
the control of the pituitary gland hormones (Herskovits and Guarente, 2014) . 
Normally, brain SIRT1 levels, especially in the hypothalamus change in response to diet, and 
appear to mediate numerous aspects of hypothalamic control. Depending on the type of diet SIRT1 
levels are downregulated by a high fat diet  (Ramadori and Coppari, 2011). For example, absence 
of SIRT1 blocks the somatotropic axis, which plays an important role in the co-ordination of 
protein and energy metabolism. On the other side, during CR/dietary restriction (CR/DR) and 
physical exercise, SIRT1 levels may increase in neurons, and at the same time increase neural 
activation in the dorsomedial hypothalamic nucleus (DMH) and lateral (HL) (Satoh et al., 2010). 
Moreover, in the anoxerigenic pro-opiomelanocortin (POMC) neurons, responsible for regulating 
the hunger and food intake, localized in the arcuate nucleus of the hypothalamus, SIRT1 is 
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essential for maintaining the normal energy level according to diet. Recently studies have shown 
the crucial role of SIRT1 in metabolic homeostasis through its activity in these neurons (Ng, 
Wijaya and Tang, 2015). It is also well known that SIRT1 regulation of energy (glucose and lipid) 
metabolism has been so far correlated with induction of hepatic gluconeogenesis, pancreatic 
insulin secretion, increased muscle insulin sensitivity and the “browning” of white adipose tissues. 
In support of this, studies in SIRT1-knockout mice showed POMC neurons are more susceptible 
to obesity. Besides, energy expenditure is reduced, as well as signaling processes induced by the 
satiety hormone leptin (Michan and Sinclair, 2007). In the CNS, SIRT1 levels decline with age 
and its overexpression in brain counters the aging-associated circadian function defects. Central 
control of the mammalian circadian rhythm exists in the hypothalamic suprachiasmatic nucleus 
(SCN), which is regulated by a feedback of transcription factor interactions. Furthermore, the 
overexpression of SIRT1 in transgenic mice could delay aging process and prolong their survival 
(Ramadori et al., 2010; Ng, Wijaya and Tang, 2015). 
A few articles have described that an optimal function of SIRT1 would be crucial for the 
maintenance of synaptic plasticity, learning and memory processes, necessary for a better 
development of cognition. Only recently was clarified the role of SIRT1 in the physiologically 
unperturbed versions of learning and memory processes. The SIRT1 hippocampal expression in 
mice also enhances learning and memory (Braidy et al., 2012; Ng, Wijaya and Tang, 2015). 
It was shown that SIRT1-deficient mice had a grossly normal brain anatomy, but in contrast 
it was noticed a deficient dendritic development phenotype. On these mice, some defects in 
synaptic plasticity, such as basal synaptic transmission were indistinguishable from wild type. In 
a few behavioral tests, short-term memory, long term associative memory, as well as spatial 
learning were all impaired in SIRT1 knock-outs compared to control  (Michán et al., 2010). These 
evidences show how important SIRT1 role plays on our nervous system. 
 
1.13 SIRTs and Neurodegenerative disorders 
 
Neurodegenerative disorders are characterized by a progressive nervous system dysfunction, 
associated with atrophy of the affected central or peripheral nervous system structures. For this 
reason, scientists have been focused to understand the mechanisms responsible for human 
neurodegeneration and the exact sequence of events that trigger the neurodegenerative processes 
leading to different disorders, including AD, PD, HD and ALS, among others (Woulfe, 2008). 
Many research studies conducted and published have been already demonstrated the 
important role of SIRTs family, that are involved in numerous processes, including 
neuroinflammation (Vachharajani et al., 2016), energy balance and melanocortin system (Toorie 
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and Nillni, 2014) and UPS (Sampaio-Marques and Ludovico, 2015); and the regulation of the  
CNS (Satoh, Stein and Imai, 2011).  
Therefore, these many evidences show the greatest potential of SIRTs as therapeutic 
candidates for intervention in various diseases, especially in neurodegeneration and 
neurodegenerative disorders. 
 
1.13.1 The Link between SIRT1 and AD 
 
SIRT1 deacetylase is often involved with a range of neuropathological conditions. In human 
AD brains, SIRT1 levels appear to be decreased in parietal cortex, which may correspond to some 
brain regions affected during AD progression from early to late stages (Wong and Tang, 2016). In 
addition, some studies have mentioned that a lower cortical SIRT1 was correlated with the duration 
of symptoms, reduced global cognition scores, and accumulation of Aβ and Tau proteins in the 
cerebral cortex. 
For this reason, multiple evidences suggest that an upregulating SIRT1 in the brain in mouse 
models of AD, and these increasing SIRT1 levels may promote neuronal survival, playing a 
neuroprotector role in both AD condition and dementia (Ma et al., 2014).  
Data have described that SIRT1 activation by resveratrol (RSV), a SIRT1 activator, in 
transgenic mice models, could cross the BBB, protecting against toxicity and promoting 
neuroprotection in general (Della-Morte et al., 2009). RSV improves neuronal cell survival in 
response to oxidative stress events and protects also neuronal cells from ischemic insults. These 
protect responses are involved with a RSV-induced increase in hippocampal SIRT1 activity 
(Raval, Dave and Pérez-Pinzón, 2006).   
At the other sight, other studies have noticed that in AD mice model transgenic, an 
overexpression of SIRT1 decreases amyloid plaques accumulation, and at same time decline 
learning and memory capabilities, whereas brain SIRT1 specific knock-out had attenuated lifespan 
(Qin et al., 2006).  
These studies have been focused on Aβ formation, where an overexpression of SIRT1 in primary 
neurons, decreased Aβ secretion and diminished Rho-activated kinase 1 (ROCK1) expression.  
Moreover, another pathway where SIRT1 plays a neuroprotection role is through the NF-ĸB 
route preventing Aβ neurotoxicity due to decreased microglial expression of NF-ĸB (Chen et al., 
2005). 
It is believed that higher concentrations of Aβ lead to modifications of Tau protein. 
Evidences have been suggested that conversion from normal Tau protein into insoluble PHF shares 
CHAPTER 1 
37 
 
 
common mechanism pathways with the decrease in SIRT1 in AD pathology, linking SIRT1 
deacetylase concentration to the severity of the disease (Julien et al., 2009).  
SIRT1 has also been shown to ameliorate Tau pathology in the p25 mouse model, affecting 
cognitive impairment and mortality. Cyclin-dependent kinase 5 (Cdk5) and its regulatory subunit 
p35 are integral players in the proper development of the mammalian CNS. The p25 results from 
the proteolytic cleavage of p35 subunit leading to an aberrant Cdk5 activation. When the plasticity 
is compromised, the formation of p25 occurs as a compensatory mechanism at an early stage of 
AD ailment (Michán et al., 2010). 
Finally, a recent approach important on AD malady is the autophagy-lysosomal pathway, 
directing the modified-release proteins, as well as dysfunctional organelles, involving several 
proteins, which in somehow depend on the regulation of SIRT1 activity. More studies are needed 
to understand the influence of SIRT1 in both Aβ and Tau proteins, and in this specifically network, 
autophagy-lysosomal pathway. 
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2 AIMS 
 
According to World Health Organization (WHO), neurologic disorders are a serious public 
health problem in our society, affecting millions of people worldwide. Population is ageing rapidly 
and as an example, the total number of people with dementia is expected to increase to 82 million 
in 2030 and 152 million in 2050 (WHO, 2017). 
One of the most prevalent malady among elderly adults, included in these complex group of 
diseases, responsible for memory impairment and dementia is AD, which still have not an effective 
medicine to treat the symptoms, slow, prevent or reverse the progressive deterioration of neuronal 
structures, occurring specifically in CNS. A vital homeostatic mechanism in healthy cells, an 
important cytoprotective response in a scenario of aging- and disease-related metabolic challenges 
is autophagic pathway, that has been implicated in the pathogenesis of major neurodegenerative 
disorders. 
Impairment at different stages of autophagy leads to the buildup of pathogenic proteins and 
damaged organelles. At the beginning stage of autophagy, Beclin-1, one of the starters and 
essential proteins is decreased in AD patients, leading for an eventual impairment on autophagic 
flux. 
Therefore, bearing in mind (i) The impact of brain disorders as one of the most serious 
problems facing modern society, (ii) the unpaired homeostasis process responsible for degradation 
of damaged proteins and organelles in neurodegenerative diseases, (iii) the unclear cause of 
decreased Beclin-1 levels in brain of AD patients and (iv) considering the use of cybrids as a 
cellular model for this study, we aimed: 
 
1. To evaluate Beclin-1 acetylation levels in MCI and AD; 
2. To understand the impact of (de)acetylation of Beclin-1 on autophagic flux; 
3. To evaluate how (de)acetylation will affect lysosomal function and localization. 
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3 MATERIALS AND METHODS 
 
3.1 Reagents 
 
NAM, Leupeptin and MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
were purchased from Sigma Chemical Co. (St. Louis, MO, USA). 
Ammonium Chloride (NH4Cl) was obtained from Merck KGaA (Darmstadt, Germany) and 
C646 was purchased from Calbiochem, Merck KGaA (Darmstadt, Germany). 
 
3.2 Antibodies 
 
For Immunoblotting analysis, the following secondary antibodies were used and the working 
dilutions are given in brackets: Goat anti-mouse IgG alkaline phosphatase conjugated antibody 
(1:10,000) from Thermo Fisher Scientific Inc. (Rockford, IL, USA) and Goat anti- rabbit IgG 
alkaline phosphatase conjugated antibody (1:20,000) was from GE Healthcare (Bio- Sciences, 
Uppsala, Sweden). 
The following primary antibodies were used and the working dilutions are given in brackets: 
mouse monoclonal anti-Cathepsin D (C-5) antibody (1:1000) was from Santa Cruz Biotechnology, 
Inc. (Santa Cruz, CA, USA); rabbit polyclonal anti-SIRT1 (D739) antibody (1:1000), rabbit 
polyclonal anti-Phospho-SIRT1 (Ser47) antibody (1:2000), rabbit polyclonal anti-Beclin-1 
antibody (1:1000), rabbit polyclonal anti-Rab7 antibody (1:1000), rabbit polyclonal anti-LC3B 
antibody, mouse monoclonal anti--tubulin (11H10) antibody (1:1000), rabbit polyclonal anti-
Acetylated-Lysine antibody (1:1000) all were from Cell Signaling Technology, Inc. (Danvers, 
MA, USA); rabbit polyclonal anti-p62 antibody (1:1000), mouse monoclonal anti--Actin 
antibody (1:5000), all from Sigma (St. Louis, MO, USA). LAMP-2A (1:100) from Santa Cruz 
Biotechnology, Inc. (Santa Cruz, CA, USA). For Immunoprecipitation, Acetylated-Lysine 
antibody (1:500) was used from Cell Signaling Technology, Inc. (Danvers, MA, USA), and for 
Immunofluorescence was used LAMP-1 antibody (1:100) from Hybridoma Bank, USA. 
 
3.3 Cell Culture 
 
3.3.1 Human Subjects 
 
Subject participation was approved by the Kansas University Medical Center’s Institutional 
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Review Board. For this study subjects were recruited from the University of Kansas Alzheimer’s 
disease Center (KU ADC). Additionally, each subject was determined, based on cognitive testing 
and by a memory disorders subspecialist clinician, to meet criteria for normal cognition-control 
status (CT), MCI, or sporadic AD (sAD). After providing informed consent, sAD (n=8), MCI 
(n=7), and CT (n=7) subjects underwent a 10 ml phlebotomy using tubes containing acid-citrate-
dextrose as an anticoagulant. The age of the sAD subject platelet donors was 71.5 ± 9.7 years, the 
age of the MCI platelet donors was 72.3 ± 6.6, and the age of the CT subject platelet donors was 
73.9 ± 7.7 (Silva et al. 2016). 
 
3.4 Creation of Cybrid Cell Lines 
 
Cytoplasmic hybrid (cybrid) technique was first described by King and Attardi, that consists 
in the transfer of mitochondrial (mtDNA) exogenous to mtDNA-depleted recipient cells (Rho 0 
line cells), generating cybrids (King and Attardi, 1989). The cybrids were created from a SH-
SY5Y cell nuclear background by the KU ADC Mitochondrial Genomics and Metabolism Core 
(Miller et al., 1996). To generate the cybrid cell lines used in this study, we used platelets from 
human subjects, as already referred, CT, MCI and sAD, which were mixed with SH-SY5Y cells 
previously depleted of endogenous mtDNA (Rho 0 cells) as previously described (Swerdlow et 
al., 1996; Arduino, 2012) (Figure 3.1). 
During the overall cybrid generation procedure, several different types of media were used. 
Dulbecco’s modified Eagle’s medium: Nutrient Mixture F-12 (DMEM/ F-12) was obtained from 
Gibco-Invitrogen (Life Technologies Ltd, UK), while non- dialyzed FBS was obtained from Sigma 
(St. Louis, MO, USA). SH-SY5Y Rho 0 cell growth medium consisted of DMEM/F-12 
supplemented with 10 % non-dialyzed FBS, 200 μg/ml sodium pyruvate obtained from Sigma (St. 
Louis, MO, USA), 150 μg/ml uridine obtained from Sigma (St. Louis, MO, USA), and 1 % 
penicillin–streptomycin (pen-strep) solution. The SH-SY5Y cybrid selection medium consisted of 
DMEM/F-12 supplemented with 10 % dialyzed FBS and 1 % pen-strep solution. The selection 
process lasted 6 weeks. After cell line selection was completed, each line was continuously 
maintained in a cybrid growth medium containing DMEM/F-12 supplemented with 10 % non- 
dialyzed FBS and 1 % pen-strep solution for over 2 months prior to biochemical and molecular 
assays (Silva et al., 2016). 
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Figure 3.1 - Cybrid results from the repopulation of the Rho 0 cell line with mtDNA exogenous. Rho 0 cell line results from 
the elimination of mtDNA of immortalized cell lines by the presence of ethidium bromide. Rho 0 cells are then fused with patient 
platelets, which contain mitochondria but not nuclei. In this case, mtDNA exogenous is derived from platelets isolated from 
different individual disease-free CT, MCI and sAD subjects. So, differences in function between CT, MCI and sAD cybrids cell 
lines likely arise through differences in their mtDNA. Adapted from (Arduino, 2012) 
 
 
3.5 Cell Media and Treatments 
 
Cells were grown in 75 cm2 tissue culture flasks maintained in a humidified incubator at  
37 ºC and 5 % CO2. For the MTT assay, cells were plated in 24-well plates at a density of 0.2 × 
106 cells/ml. For Western blot analysis and Immunoprecipitation assay cells were plated in 6- well 
plates at a density of 0.25 × 106 cells/mL or in petri-dishes (10 cm). For immunocytochemistry 
analysis, cybrid cell lines were grown on coverslips in 12-well plates at a density of 0.1 × 106 
cells/ml. 
Prior to experiments, cell lines were maintained in the cybrid growth medium, cybrids 
containing DMEM supplemented with 10 % non-dialyzed FBS and 1 % pen–strep solution. 
Cybrid cell lines were incubated for 6 h with 5 mM NAM, a SIRT1 inhibitor or with 2,5M 
C646, a p300 inhibitor. Autophagy modulation consisted of the treatment of the respective cell line 
with 20 mM NH4Cl and 10 mM Leupeptin for 4 h. For all experimental procedures, controls were 
performed in the absence of those agents. 
  
Naïve neuronal- like cell line
SH-SY5Y (Neuroblastoma)
Enucleated patient
platelets
PEG Fusion
- Uridine/ Pyruvate
Cytoplasmic hybrid
(Cybrid) 
Ethidium Bromide
90-120 days
mtDNA removed
+ Uridine/ Pyruvate
SH-SY5Y-Rho 0 cell line
mtDNA (-)
5-6 weeks
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3.6 Cell Proliferation Assay 
 
3.6.1 MTT Reduction Test 
 
The MTT cell proliferation assay measures the cell proliferation rate and conversely, when 
metabolic events lead to apoptosis or necrosis, the reduction in cell viability (Mosmann, 1983). 
Cells proliferation was determined by this colorimetric method, MTT. In viable cells, the 
enzyme succinate dehydrogenase metabolizes MTT into a formazan that absorbs light at 570 nm. 
Following the cell treatment protocol the medium was aspirated and 0.5 ml MTT (0.5 mg/ml) was 
added to each well. The plate was then incubated at 37 °C for 1 h 30 m protected from light. At 
the end of the incubation period the formazan precipitates were solubilized with 0.5 ml of acidic 
isopropanol (0.04 M HCl/ isopropanol). The absorbance was measured at 570 nm (Esteves et al., 
2010). Cell reduction ability was expressed as a percentage of the CT cybrids. 
 
3.7 Preparation of Cellular Extracts 
 
3.7.1 Preparation of Whole Cellular Extracts 
 
Individual cells lines were washed with Phosphate-Buffered Saline 1  (PBS), lysed on ice 
in a hypotonic lysis buffer containing 1 % Triton X-100, 25 mM 4-(2-hydroxyethyl)-1- 
Piperazineethanesulfonic Acid (HEPES), pH 7.5, 2 mM Magnesium Chloride (MgCl2), 1 mM 
Ethylenediamine Tetraacetic Acid (EDTA), 1 mM Ethylene Glycol-bis (β-aminoethyl Ether)- 
N,N,N',N'-tetraacetic Acid (EGTA) and supplemented with 2 mM Dithiothreitol (DTT) and 
protease inhibitors [0.1 mM Phenylmethane Sulfonyl Fluoride (PMSF), and a 1:1000 dilution of a 
commercial protease inhibitor cocktail]. Cell were then scrapped on ice. Subsequently, cell 
suspensions were frozen three times in liquid nitrogen and centrifuged at 20,000  g for 10 min. 
The resultant supernatant was removed and stored at -80 °C. Protein content was determined using 
Bradford Protein Assay (Bio-Rad, Hercules, CA, USA). 
 
3.7.2 Preparation of Cytosolic and Nuclear Cellular Extracts 
 
Cell lines were washed with PBS (1 ), lysed on ice in a first buffer, Buffer I containing 10 
mM HEPES, 10 mM NaCl, 3 mM MgCl2, 1 mM EGTA, pH 7.5, supplemented with 0.1 % Triton 
X-100, with 1 mM DTT, with protease inhibitors [1 mM DTT, 1 mM PMSF and 1:1000 dilution 
of a commercial protease inhibitor cocktail] and with phosphatase inhibitors [2 mM Sodium 
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Orthovanadate (Na3VO4) and 50 mM of Sodium Fluoride (NaF)]. Cells were then scraped on ice. 
Afterwards, cell suspensions were centrifuged at 2,300  g for 10 min at 4 ºC. The resulting 
supernatant was the cytosolic fraction. Then, the resulting pellet was resuspended in a second 
buffer, Buffer II containing 20 mM HEPES, 300 mM NaCl, 5 mM MgCl2, 0.2 mM EGTA, 20 % 
Glycerol, pH 7.5, supplemented with 1 mM DTT, 1 mM PMSF and 1:1000 dilution of a 
commercial protease inhibitor cocktail. Cell suspensions were centrifuged at 12,000  g for 20 min 
at 4 ºC. The resulting supernatant was the nuclear fraction. Both fractions were stored at -80 °C. 
Protein content was determined using Bradford Protein Assay (Bio- Rad, Hercules, CA, USA). 
 
3.8 SDS-PAGE and Immunoblotting 
 
For Western Blot analysis samples were resuspended in 6  sample buffer (4  Tris. HCl 
/SDS; pH 6.8, 30 % glycerol, 10 % SDS, 0.6 M DTT, 0.012 % bromophenol blue) under reducing 
conditions. Depending on the protein molecular weight, samples containing 30 g of protein 
were loaded onto accordingly percent SDS- Polycrylamide (SDS-PAGE) gels. Specifically, for the 
analysis of LC3, LAMP-2A and Cathepsin D, samples were separated by electrophoresis on a 15 
% gel and all the other protein samples were separated by electrophoresis on a 10 % gel. After 
electrophoresis, gels were transferred to Polyvinylidene Difluoride (PVDF) membranes 
(Millipore, Billerica, MA, USA). Subsequently, non-specific binding was blocked by gently 
agitating the membranes in 3 % Bovine Serum Albumin (BSA) for 1 h at room temperature. The 
blots were subsequently incubated with the respective primary antibodies overnight at 4°C with 
gentle agitation. The next day, membranes were washed in Tris-Buffered Solution (TBS) contain 
0.1 % Tween, three times, each time for 5 min, and then incubated with the appropriate horseradish 
peroxidase-conjugated secondary antibody for 2 h at room temperature with gentle agitation. After, 
three washes specific bands of interest were detected by developing with an alkaline phosphatase 
enhanced chemical fluorescence reagent (ECF from GE Healthcare). Fluorescence signals were 
detected using a Biorad Versa-Doc Imager. 
 
3.9 Immunoprecipitation assay 
 
Cells were scraped in buffer containing 20 mM Tris, 100 mM NaCl, 2 mM EDTA, 2 mM 
EGTA (pH 7.0), and protease inhibitors (100 mM PMSF and a commercial protease inhibitor 
cocktail). CT, MCI and sAD cybrids cell suspensions were centrifuged at 20,000  g for 10 min at 
4 °C. Supernatants were collected and stored at -80 °C. Protein content was determined using 
Bradford Protein Assay (Bio-Rad, Hercules, CA, USA) and 500 μg of cell lysates were incubated 
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with the Acetylated-Lysine (1:500) primary antibody overnight at 4 °C, and with gentle agitation. 
Lysates were then incubated with 100 μL of protein-A beads for 2 h at 4 °C and with gentle 
agitation. After completing this incubation, lysate tubes were centrifuged at 65  g for 5 min at 4 
°C, the supernatant was removed, and the beads were washed buffer five times (each time 
centrifuging at 4 °C and removing the supernatant). For the two first washes, the buffer was 
supplemented with 1 % Triton X-100. For the next two washes, the buffer was supplemented with 
1 % Triton X-100 and 5 mM NaCl. The two final washes were performed with unsupplemented 
buffer. Finally, the last supernatant was removed, and 25 μL of sample buffer (2 ) was added. 
The sample was boiled at 95-100 °C for 5 min to denature the protein and to separate it from the 
protein-A beads. The boiled proteins were centrifuged at 20,000  g for 5 min at room temperature, 
and the supernatants were collected. The resulting immunoprecipitated samples were separated by 
SDS-PAGE and subjected to Western Blot analysis using anti-Beclin-1 antibody and anti-
Acetylated-Lysine antibody, as previously described. 
 
3.10 Immunofluorescence and Confocal Microscopy 
 
Cybrid cells were washed with PBS (1 ) and fixed for 30 min at room temperature using 4 
% paraformaldehyde. Fixed cells were then washed again with PBS (1 ), permeabilized with 
methanol at -20 °C for 30 min and blocked with 3 % BSA for 30 min. 
Afterwards, cells were incubated with primary antibodies (1:100 anti-LAMP-1 (H4A30) 
from the Developmental Studies Hybridoma Bank (University of Iowa, Iowa City, IA, USA) 
overnight in a wet chamber at 4 °C. Later, cells were incubated 1 h with the appropriate secondary 
antibody (1:250 AlexaFluor 488 or 594 from Molecular Probes, Eugene, OR, USA). Finally, cells 
were washed in PBS (1 ), incubated for 5 min with Hoechst (15 μg/μL) in the dark. Cells were 
then washed twice in PBS (1 ) and the coverslips were immobilized on a glass slide with 
mounting medium DakoCytomation (Dako, Glostrup, Denmark). Confocal images were obtained 
using a Plan-Apochromat/1.4 NA 63 x lens on an Axio Observer. Z1 confocal microscope (Zeiss 
Microscopy, Germany) with Zeiss LSM 710 software. 
LAMP-1-positive clusters per cell were quantified using the “analyze particle” function of 
the ImageJ, as previously described by Bandyopadhyay and colleagues (Bandyopadhyay et al., 
2014). Punctate lysosomes were selected with a size ≤ 0.2 μm, whereas lysosomes clusters were 
selected with a size between 0.2 μm and 5 μm. LAMP-1 fluorescence intensity was quantified using 
ImageJ v1.39 k (National Institute of Health, USA) program. 
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3.11 Data acquisition and Analysis 
 
All data result was expressed as mean ± Standard Error of the Mean (SEM) in at least three 
independent experiments. Statistical analyses were performed using one-way Analysis of Variance 
(ANOVA) followed by Bonferroni Multiple-Comparisons Procedure as post-hoc test. Analyses 
and graphical presentation were performed with the GraphPad Prism software version 5 (GraphPad 
Software, Inc., San Diego, CA, USA). To compare means between two groups we used two-way, 
unpaired Student’s T-tests, with p-values lower than 0.05 (p < 0.05), which were considered 
significant. 
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4 RESULTS 
 
4.1 Effect of NAM and C646 on toxicity in cybrid cell lines 
 
We used in our cellular model, as a parameter of cell viability, the MTT assay to establish 
nontoxic concentrations of NAM, a SIRT1 deacetylase inhibitor (Wang et al., 2013) and C646, a 
relatively potent, selective, cell-permeable small molecule inhibitor of p300 lysine 
acetyltransferase (Shrimp et al., 2015). 
 
 
Figure 4:1 – Effects of NAM and C646 on MTT reduction test. Cybrid cell lines were incubated with NAM at concentrations 0.5 
mM, 1mM, 5mM and 10mM (A). Cybrid cell lines were incubated with concentrations 1 µM, 2.5 µM, 5 µM, 10 µM and 20 µM 
of C646 (B). 
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4.2 SIRT1 and p300 roles in acetylation of Beclin-1 in cybrid cellular model 
 
SIRT1, a phylogenetically conserved NAD+ - dependent histone deacetylase has been 
described to play a predominant role in autophagy induction under starved conditions, regulating 
the deacetylation of multiple essential proteins involved in autophagy network (Jazwinski, 
Belancio and Hill, 2017).  
Lee et al. (Lee et al., 2008) have described that SIRT1 deacetylase is clearly an essential 
regulator of autophagic degradation both in vitro and in vivo conditions (Lee et al., 2008). 
Besides cellular deacetylases, regulation of autophagy activity can be provided by additional 
enzymes, responsible for catalyzing the forward acetylation reaction. Acetylation process is 
increasingly recognized as one of the major post-translational mechanism for the regulation of 
multiple cellular functions in mammalian cells. 
Acetyltransferase p300 is a critical regulator of eukaryotic gene expression, involved in 
several biological processes (Ghosh and Varga, 2007) and the related cyclic AMP (cAMP) 
response element-binding protein (CREB), serve as transcription coactivator by acetylating core 
histones and nuclear non-histones proteins. p300 is predominantly nuclear but can shuttle between 
the nucleus and cytoplasm and recently has been suggested to participate in the regulation of 
autophagy pathway. Various Atg proteins, such as LC3 and Atg5 are targeted by p300-mediated 
acetylation, leading to an inhibition of their autophagic activities (Wan et al., 2017). 
A dysregulation of histone acetylation has been described in a diversity of signal transduction 
pathways, including cell differentiation, cell apoptosis, vascular remodeling, inflammation 
reaction, immune responses, neuronal plasticity, among others (Lu et al., 2015). An altered 
acetylation in non-histone proteins, nuclear and cytoplasmic, has been related to AD pathology, 
such as Tau protein (Irwin et al., 2012), -tubulin (Perez et al., 2009; Silva et al., 2016), p53 
(Chang et al., 2011) and NF-B (Chen et al., 2001). For this reason, we found interesting to 
understand the role of histone acetyltransferase p300 using a specific inhibitor-C646, as well an 
inhibitor-NAM for deacetylase SIRT1. 
First, we evaluate the levels of phospho-SIRT1 (p-SIRT1), SIRT1 active form, in our cybrids 
cellular model. Our results point to a significantly decreased of basal p-SIRT1 in sAD cybrid cell 
line compared to MCI and CT cybrid cell lines (Figure 4.2 A), which is in accordance to previous 
results (Kumar et al., 2013; Silva et al., 2016). In fact, we observed that under basal conditions p-
SIRT1 levels are very similar between MCI and CT groups, indicating what was described by 
Julien and colleagues (Julien et al., 2009). This observation suggests that measurement of p-SIRT1 
levels are of no value as a marker in the early stages of AD condition. Additionally, we did not see 
any significantly effect of NAM. When used C646, we noticed an increase of p-SIRT1levels in 
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MCI cells, but a decrease in sAD cells. Moreover, we found a decreased ratio between 
nuclear/cytosolic SIRT1 in sAD cybrid cell line, similarly to what was observed by Silva and 
coworkers (Silva et al., 2016) (Figure 4.2 B). These results indicate that the SIRT1 localization 
patterns differ between “normal cells” and “cells with disease”. 
Afterwards, we want to understand in our cybrids cellular model, how an inhibition of SIRT1 
and p300 would affect Beclin-1 protein levels in our cell lines. Beclin-1 is an essential molecular 
anchor in autophagy pathway, regulating the initiation and nucleation of autophagosomes 
formation (McKnight and Zhenyu, 2013). Studies have described that Beclin-1 expression is 
significantly decreased in samples from AD brains, when compared with age- matched controls 
(Pickford et al., 2008; Jaeger and Wyss-Coray, 2010). Moreover, Jaeger and colleagues (Jaeger et 
al., 2010), have been described that a deficiency of Beclin-1 expression affects the degradation of 
autophagosomes in cultured cells. In our study using cybrid cells, Beclin-1 protein levels are 
reduced in basal sAD group, comparing with MCI and CT groups. At the same time, we see an 
increase of Beclin-1 in sAD cybrid cellular line when SIRT1 is inhibited, which may be related to 
altered acetylation leading to an impairment of autophagy pathway in AD pathology, described 
already (Uddin et al., 2018). Although, MCI and CT groups show a slight decrease when treated 
with NAM, comparing with sAD group. Inhibiting p300, we noticed a decrease of acetylation 
levels in sAD cell line, as expected, but an increase in both MCI and CT cell lines (Figure 4.2 C). 
These evidences indicate that acetylation may play a role in autophagy regulation, namely alteration 
of Beclin-1 acetylation status in AD malady. Finally, with these interesting results we wanted to 
understand if acetylated Beclin-1 is in fact increased in our cellular model. We found that basal 
levels of acetylated Beclin-1 are significantly increased in sAD group, but not in MCI and CT 
groups. Curiously, the total of lysine-acetylation basal levels is in opposite way compared to basal 
acetylated Beclin-1 levels in sAD cybrid cells, significantly decreased compared with CT and MCI 
cybrid cells (Figure 4.2 D). 
Afterwards, we observed that an inhibition of SIRT1 deacetylase increases significantly 
acetylated Beclin-1 levels in sAD group comparing to MCI and CT groups. These also interesting 
results, suggest the essential role played by SIRT1 in AD pathology. In addition, an inhibition of 
p300 acetyltransferase, leads to a slight decrease of acetylated Beclin-1 protein levels in MCI cybrid 
cell lines. When we used NAM, the total lysine-acetylation levels, showed a tendency to increase 
in CT, MCI and sAD groups. Plus, when we used C646, only in the CT cell line, the levels of the 
total lysine-acetylation were significantly decreased. (Figure 4.2 E). 
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Figure 4:2 - SIRT1 and p300 roles in acetylation of Beclin-1 in cybrid cellular model. Immunoblotting for phospho-SIRT1 
protein levels for each separate cybrid group treated with NAM and C646 (A). Immunoblotting for nuclear and cytosolic SIRT1 levels 
for each separate cybrid group treated with NAM (B). Immunoblotting for Beclin-1 protein levels for each separate cybrid group 
treated with NAM and C646 (C). Immunoprecipitation for acetylated Beclin-1 basal levels and for total Lysine-Acetylated basal 
protein levels (D). Immunoprecipitation for acetylated Beclin-1 and for total Lysine-Acetylated protein levels for each separate 
cybrid group treated with NAM and C646 (E). * indicates a p < 0.05 difference from the control CT cybrid cell line; *** indicates 
a p < 0.001 difference from the control CT cybrid cell line. Data were analyzed by Student’s T-test and are presented as mean  
S.E.M. 
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4.3 Autophagic flux- a link to pathophysiological processes in AD 
 
To elucidate further about autophagy network, we decided to analyze two important 
proteins in our cybrid cellular model, involved on autophagic flux. 
The first one, LC3 protein has been widely used to monitor the number of autophagosomes, 
as well as autophagic activity, being responsible for controlling the major steps in the autophagy 
pathway, including the growth of autophagic membranes, recognition of autophagic cargoes, and 
the fusion of autophagosomes with lysosomes (Huang and Liu, 2015). LC3 is localized in both 
nucleus and cytosol, implying that the protein can shuttle between the two cellular compartments. 
Recent studies have described that during starvation, deacetylation by SIRT1 promotes LC3 
redistribution from the nucleus to cytosol, where it associates with Atg7 protein, and with the rest 
of autophagy core machinery to form autophagosomes (Lee and Lee, 2016). 
During the generation of autophagosomes membranes, cytosolic LC3I (resides in cytosol; 
free form) is conjugated to PE through two consecutive ubiquitylation-like reactions catalyzed by 
the E1-like enzyme Atg7 and the E2-like enzyme Atg3 to LC3II form (membrane bound). The 
intra-autophagosomal LC3II is degraded in autolysosomal lumen by lysosomal hydrolases during 
the fusion of autophagosomes with lysosomes. 
For all these reasons, we decided to evaluate LC3II levels to monitor the autophagosomes 
membranes levels, as a purpose to investigate autophagic flux (Deretic, 2008) . 
We observed that autophagic flow is significantly decreased in sAD group, when compared 
with MCI and CT groups. This decrease may represent an aberrant activation of autophagy 
pathway or a defective clearance of AVs. However, after SIRT1 deacetylase inhibition, we noticed 
a significantly decrease of autophagic flow in CT cybrid cell line compared with both MCI and 
sAD cybrid cell lines. These findings may be in accordance with the hypothesis that SIRT1 might 
deacetylate LC3 (Lee et al., 2008). Deacetylation by SIRT1 is necessary for LC3 to shift its 
distribution from the nucleus to cytoplasm during cell starvation (Huang and Liu, 2015) and 
probably in pathological conditions, such as AD pathology. C646 increased significantly the 
autophagic flow in sAD cybrid cells (Figure 4.3 A). 
These observations also may suggest that modulation of acetylation-deacetylation cycle of 
LC3 can affect the subcellular distribution of LC3 protein and the cytoplasmic redistribution of 
LC3 protein dependent on deacetylation event of LC3, leading to a possible dysfunction of 
autophagic flux. Furthermore, these notes can suggest that a Beclin-1 acetylation can promote 
Beclin-1-rubicon interaction, affecting or inhibiting autophagosome maturation and endocytosis, 
inducing to a decrease of autophagic flow in AD pathogenesis. 
 
58 
CHAPTER 4 
 
 
 
Other protein, extremely important in autophagy pathway is p62 involved in protein turnover, 
widely used as a marker for autophagic flux. p62 is a multifunctional protein, and plays some 
important functions through oxidative stress, autophagy and proteasome, as an adaptor protein to 
transport ubiquitinated and misfolded proteins for proteasomal and autophagic degradation 
(Caccamo et al., 2017).  
Also, p62 plays functions as an adaptor or cargo receptor in degradation of ubiquitinated 
proteins, and organelles, including mitochondria and peroxisomes. Additionally, a recent study 
has described that p62 self-oligomerization is important for its localization to the autophagosome 
formation site, being associated to ER, occurring in an independently LC3 process manner (Itakura 
and Mizushima, 2011). Importantly, p62 acts as a substrate during autophagy pathway 
degradation, and an increase levels of p62 protein suggests that autophagic flux may be impaired 
(Tanji et al., 2014). In p62 knockout mice show age-dependent accumulation of  NFTs and synaptic 
deficits underlying the role of p62 in Tau protein aggregation and degradation (Caccamo et al., 
2017). In AD condition, p62 is strongly bind to NFTs, mostly likely to target them for degradation. 
Thus, p62 is also related to deliver ubiquitinated proteins, such as Tau protein, to the proteasome 
for clearance (Liu et al., 2016). Studies using AD brain tissue described that p62 protein levels are 
decreased, being directly associated with an increase of protein aggregation and deposition (Du et 
al., 2009). 
Therefore, we decided to evaluate p62 protein levels in our cybrid cellular model. First, we 
noticed that in both MCI and sAD untreated groups, the flux of p62 was significantly decreased 
compared to CT untreated group, as expected. These observations may indicate that p62 
accumulation is due to inefficient autophagy network (Du et al., 2009; Du, Wooten and Wooten, 
2009). Although, treatment with C646 leads to an extreme increase of p62 flux in sAD cybrid cell 
line, comparing to both MCI and CT cybrid cell lines, indicating that an inhibition of acetylation, 
including of Beclin-1, may be in part benefic in AD condition (Figure 4.2 B). Indeed, Nixon and 
colleagues (Haung Yu et al., 2005) showed in post-mortem human AD brains an accumulation of 
autophagosomes, suggesting deficits in autophagy flux in neurodegenerative disorders (Haung Yu 
et al., 2005).  
At the same time, these results may suggest that acetylation mechanism, specifically, 
involved with Beclin-1 protein, can influence both LC3 and p62 protein levels to be degraded after 
autophagosome maturation and fusion with lysosome, which might compromise the regulation of 
autophagic flux.
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Figure 4:3 -Autophagic flux- a link to pathophysiological processes in AD. Immunoblotting for LC3II protein levels for each 
separate cybrid group, untreated and treated with NH4CL/Leupeptin-NAM and NH4CL/Leupeptin-C646 (A). Immunoblotting for 
p62 protein levels for each separated cybrid group, untreated and treated with NH4CL/Leupeptin-NAM and NH4CL/Leupeptin-
C646 (B). * indicates a p < 0.05 difference from the control CT cybrid cell line; *** indicates a p < 0.001 difference from the 
control CT cybrid cell line. Data were analyzed by Student’s T-test and are presented as mean  S.E.M. 
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4.4 Lysosomes localization and function might be affected 
 
Another pathway, essential in all most cells of our body is lysosomal network,  a sensitive 
system, important in neuronal cells, through of their extreme asymmetry, and the length of axons 
and dendrites (Pu et al., 2016).  Multiple evidences suggest that changes or even mutations in 
components of the lysosome-positioning machinery may cause neurological disorders (Ballabio, 
2016). An imbalance of autophagic flux, can lead to some diverse events, such as cell death either 
from an increase of autophagosomes generation and/ or a decrease in degradation substrates; 
disruption of axonal transport in late endosomes; lysosomes and autolysosomes accumulation in 
neurons, resulting in dystrophic axonal swellings, typically seen in AD ailment; and defects in 
lysosomal hydrolases. All of these events are responsible for an autophagy-lysosome dysfunction 
contributing to develop of neurodegenerative diseases (Tammineni et al., 2017). 
For all these reasons, lysosomal dysfunction should be investigated as a potential risk factor 
in AD condition. Therefore, we found interesting to evaluate two important proteins involved in 
lysosome network, the LAMP-2A and CatD proteins. 
The impairment of autolysosomal proteolysis system is mainly responsible for disruption of 
autophagy in early AD pathology. The progression of disease is accompanied by complex 
pathological changes, leading to a massive accumulation of LEs/MVBs, lysosomes, 
autolysosomes and autophagosomes (Nixon, 2016). The limiting membrane of lysosome contains 
more than a 100 proteins, and the most abundant are the LAMP-1 and LAMP-2, which together 
account 80% of lysosomal membrane protein content (Wartosch, Bright and Luzio, 2015). LAMPs 
are mainly localized to lysosomes, but can also be detected in lower amounts in endosomes and at 
the plasma membrane.  
LAMP-2 is one of the two different classes of LAMPs proteins, expressed in different tissues 
and present mainly in the lysosomal lumen, as well as the lysosomal membrane. Additionally, 
LAMP-2A, one isoform of LAMP-2, is a receptor for substrates of CMA, when specific cytosolic 
proteins are directly transported through the lysosomal membrane within the lysosomal matrix to 
be degraded (Cuervo and Dice, 2000). This protein is one of the three splice variants encoded by 
the LAMP-2 gene, which share identical regions and different transmembrane and cytosolic tails 
(Esteves, Oliveira and Cardoso, 2013). LAMP-2A is crucial for lysosomal protection and has been 
reported to be increased in several lysosomal storage disorders as a general response to decreased 
lysosomal clearance. However, little is known of how LAMP-2A is regulated. LAMP-2A have 
been described significantly increased in CSF from AD patients (Armstrong et al., 2014). For all 
these facts, we found interesting to evaluate LAMP-2A levels in our cybrid cellular model. 
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We observed an increase of basal LAMP-2A levels in sAD group compared with CT and 
MCI groups, as expected. This result may indicate that an accumulation of both oligomeric A1-
42 and Tau protein may be responsible for an upregulation of LAMP-2A. It was described that 
Tau protein can associate with hsc70, the cytosolic chaperone responsible for targeting substrates 
to lysosomes (Wang et al., 2009). Additionally, the presence of LAMP-2A is not sufficient to 
conclude that lysosome may be active for CMA, once not all LAMP-2A positive lysosomes can 
perform CMA pathway. An increase in LAMP-2A levels may indicate, an increase in lysosomal 
biogenesis or an upregulation to allow CMA via (Patel and Cuervo, 2015). 
Interestingly, when we treated our cells with lysosomal inhibitors, such as NH4CL/ 
Leupeptin, using NAM, we noticed that LAMP-2A levels in sAD cybrid cell line are much higher 
than in MCI and CT cybrid cell lines. This result indicates that an inhibition of SIRT1 deacetylase 
have a negative effect in CM pathway, and consequently in AD malady. However, when we used 
C646, is noticeable a decrease of LAMP-2A levels in sAD group but not in MCI group (Figure 
4.4 A). 
These observations may be associated with an acetylation of Beclin-1 by the 
acetyltransferase p300. An inhibition of p300 in sAD cybrid cell line decrease levels of LAMP-
2A, not affecting the fusion of autophagosomes with lysosomes, and CMA via. In the other hand 
an acetylation of Beclin-1 can affect the LAMP-2A receptor levels, which can influence cytosolic 
proteins degradation and consequently CMA pathway. Therefore, a deacetylation of Beclin-1 has 
a protective effect in autophagy-lysosomal pathway, lysosomes and in AD pathology. 
CatD is a soluble lysosomal aspartic endopeptidase, playing numerous physiological 
functions in the cells, such as metabolic degradation of intracellular proteins and activation of 
enzymatic precursors. Several proteins produced in neurons are physiologic substrates of CatD, 
and would be abnormally accumulate if not correctly degraded, such as APP, -synuclein and 
huntingtin. 
Actually, dysfunctions of CatD into the lysosomal system are associated to mechanisms of 
neurodegeneration (Domenico, Tramutola and Perluigi, 2016). 
Cataldo and Nixon (Cataldo and Nixon, 1990), have described that damaged neurons may 
be the principal source of cathepsins in SPs, which explains the abnormal localization of these 
enzymes and the abnormal processing of APP (Cataldo and Nixon, 1990). Other studies have been 
reported in hippocampus of MCI patient’s higher levels of CatD protein and an upregulation of its 
gene expression (Perez et al., 2015). The essential role of CatD in AD pathology is in part the 
involvement of clearance of A and Tau proteins through autophagy-lysosomal system. Therefore, 
we found interesting to analyze CatD protein levels in our cellular model. 
As expected, we observed a significantly increase of CatD protein levels in untreated sAD 
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cells.  
However, a noticeable decrease occurs in sAD group when treated with NAM. When treated 
with NH4CL/Leupeptin, a significantly decrease occurs in CT cybrid cell line. Also, an extreme 
increase of CatD levels is seen in sAD group, when treated with NH4CL/Leupeptin and NAM, 
comparing with both MCI and CT groups. This observation may suggest a compensatory 
protective mechanism when Beclin-1 acetylation is active blocking the elimination of protein 
aggregates.  
When p300 and lysosomal function are inhibited a decrease of CatD protein levels occurs in 
both CT and sAD cybrid cell lines (Figure 4.4 B). These findings may indicate that SIRT1 
deacetylase and a deacetylation of Beclin-1, can have a protective effect in autophagy-lysosomal 
network, leading to a decrease of CatD protein levels in AD condition. 
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(B) 
 
 
Figure 4:4 - Lysosomes localization and function might be affected. Immunoblotting for LAMP-2A protein levels for each 
separate cybrid group, untreated and treated with NH4CL/Leupeptin-NAM and NH4CL/Leupeptin-C646 (A). Immunoblotting for 
CatD protein levels for each separated cybrid group, untreated and treated with NH4CL/Leupeptin-NAM and NH4CL/Leupeptin-
C646 (B). * indicates a p < 0.05 difference from the control CT cybrid cell line; *** indicates a p < 0.001 difference from the control 
CT cybrid cell line; # indicates that the ANOVA calculation itself was not statistically significant. Data were analyzed by Student’s 
T-test and are presented as mean  S.E.M. 
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4.5 Endo-lysosomal fusion: an essential key on autophagic flux 
 
Finally, other pathway also extremely essential for cell biology is endo-lysosomal network, 
responsible for the transport and degradation of extracellular cargo. In mammalian, degradative 
endocytic pathway starts at the plasma membrane and ends in lysosomes. Endocytic pathway is 
responsible for controlling diverse cellular and physiological mechanisms, including the 
processing of extracellularly derived nutrients, regulation of activated surface receptors, 
maintenance of membranes homeostasis, as well as defense against external pathogens. Normally, 
internalized ligands are first delivered to endosomes and subsequently ligands or ligand-receptor 
complexes, are either delivered to lysosomes for degradation or recycled to the plasma membrane 
or Golgi complex (Cook et al., 2014). 
There are two important proteins frequently used to define LEs or MVBs and lysosomes, 
Rab7 and LAMP-1, respectively. Rab7, a small molecular weight G-protein, belongs to the Ras 
small GTPase superfamily and is involved in the maturation of autophagosomes directing the 
trafficking of cargos along microtubules, and in the fusion step with lysosomes (Vanlandingham 
and Ceresa, 2009). 
Data have been suggesting that these proteins regulate not only membrane trafficking, but 
also cell signalling, cell growth, cell survival and development. Although Rab proteins and their 
associated regulators or effectors have been implicated in various disorders, including cancer, 
pigmentation and lipid metabolism disorders and neuropathy (Zhang et al., 2009). 
Rab7 expression has been described in hippocampal neurons during the progression of AD 
pathology, suggesting that dysregulation of a select Rab GTPase phenotype is a molecular 
pathogenic marker for neuronal dysfunction in other highly vulnerable regions of the brain, early 
in the disease process (Ginsberg, Alldred, et al., 2010). Therefore, we decided first to evaluate the 
Rab7 protein levels in our cybrid cellular model.  We observed an increase in sAD group 
comparing to MCI and CT groups, in accordance with what have been reported, an upregulation 
of Rab7 in AD ailment (Ginsberg, Mufson, et al., 2010). We found that inhibitor NAM increases 
Rab7 levels only in sAD cybrid cell line. These findings suggest that an inhibition of SIRT1 
deacetylase may lead to an increase of acetylation of FOXO1, a transcription factor important in 
the regulation of autophagy pathway, leading to an autophagy inhibition. FOXO1 and Rab7 
interact with each other and an acetylation of FOXO1 can lead to higher levels of Rab7 protein 
(Bánréti, Sass and Graba, 2013). Although when p300 is inhibited occurs a decrease in sAD group 
comparing to CT and MCI groups (Figure 4.5 A). These results indicating that an acetylation of 
Beclin-1 may affect not only autophagy-lysosomal network, but also the endocytosis pathway, 
which compromise the degradation of toxic proteins, affecting neuronal cells, and leading to 
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neurodegenerative diseases. 
LAMP-1 is a glycoprotein present in luminal side of lysosomes and serves as barrier to 
soluble cathepsins and hydrolases, preventing their liberation into cytoplasm. In fact, it is an 
abundant protein component of the lysosomal membrane bearing lysosomal properties such as 
enzyme activities, pH, osmotic stability, density, morphology, and subcellular distribution 
(Eskelinen, 2006).  
Data have been reported that LAMP-1 mRNA expression levels and protein are increase in 
the cerebral cortex in AD pathology. Moreover, LAMP-1 protein is localized in the cytoplasm of 
neuronal cells, mainly those non-containing NFTs, and in glial cells surrounding SPs (Barrachina 
et al., 2006). Additionally, it has been described that lysosomal disturbances may promote A 
deposition in AD brains (Mathews et al., 2002). 
Therefore, we decided to analyze LAMP-1 protein levels in our cybrid cellular model.  
We observed that in sAD cells occurs an increase of basal LAMP-1 protein levels compared with 
MCI cells. These results suggest that a compensatory response occurs, in which cells are trying to 
eliminate AVs contents.  
Additionally, an inhibition of SIRT1 deacetylase increases the formation of clusters in both 
MCI and sAD groups, showing once more the protective role of SIRT1 protein. However, an 
inhibition of p300 acetyltransferase, decreases the clusters size in both MCI and sAD cybrid cell 
lines (Figure 4.5 B).  
These observations are in accordance with our hypothesis, that acetylation event is not 
benefic in sAD cells, leading to a global impairment of autophagy-lysosomal and endocytic 
pathways.  
Finally, is quite clear in our current study the effects of a deacetylated Beclin-1 by SIRT1 
deacetylase, that plays a crucial protective role in both autophagy and lysosomal pathways in AD 
pathology. 
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Figure 4:5 - Endo-lysosomal fusion: an essential key on autophagic flux. Immunoblotting for Rab7 protein levels for each 
separate cybrid group, treated with NAM and C646 (A). Immunofluorescence for LAMP-1protein levels for each separated cybrid 
group, treated with NAM and C646 (B). * indicates a p < 0.05 difference from the control CT cybrid cell line; *** and # indicates 
that the ANOVA calculation itself was not statistically significant. Data were analyzed by Student’s T-test and are presented as 
mean  S.E.M. 
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5 DISCUSSION 
 
A growing number of evidences have indicated some irregularities at the level of autophagy 
induction/ autophagosomes formation, as well as at lysosomal dysfunction pathway, contributing 
to the AD pathogenesis (Sooyeon, Sato and Nixon, 2011; Orr and Oddo, 2013; Salminen et al., 
2013; Liang and Jia, 2014; Lumkwana et al., 2017). 
Therefore, we propose a mechanism that might be related to the impairment of autophagy 
pathway, described in AD. Our focus was to understand how a (de)acetylation of Beclin-1, a 
beginner protein involved in autophagic pathway- responsible for the protein quality control in our 
cells, particularly essential in neurons, can be affected, and consequently, decreases autophagy 
flow, leading to a lysosomal dysfunction. 
In this study, the first step was to evaluate both roles of SIRT1 deacetylase and p300 
acetyltransferase in our cybrid cell model from CT, MCI and sAD cybrid cell lines. 
SIRT1 deacetylase is involved in regulating metabolic and aging processes in AD 
pathogenesis. Hence, it has received a widely attention in the last decades, representing a potential 
therapeutic target in neurodegenerative disorders. In addition, there is mounting evidence for a link 
between SIRT1 and AD malady. Also, SIRT1 protects against A toxicity, inhibiting NF-B 
signaling in microglia, which suggests that microglial NF-B signalling may be critical in 
mediating the toxic effects of AD-related inflammatory responses (Chen et al., 2005; Outeiro, 
Marques and Kazantsev, 2008). Data demonstrate that aging promotes the accumulation of toxic 
proteins and this process might be counteracted by anti-aging pathways. SIRTs may also regulate 
the level of these misfolded proteins by blocking their production or facilitating their removal (Gan 
and Mucke, 2008). For example, SIRT1 activation in mammalian neurons may promote -
secretase non-amyloidogenic pathway of APP processing, preventing A production, down-
regulate ROCK1 expression (Qin et al., 2006). 
Furthermore, on the autophagy machinery some evidences show that SIRT1 co-
immunoprecipitated with Atg5, Atg7 and Atg8/LC3. All these proteins could be deacetylated by 
SIRT1 in a NAD+-dependent manner in vitro (Ng and Tang, 2013). 
According to mentioned studies, we expected a reduced basal p-SIRT1 levels in sAD cell 
lines, as detected, which may generate an insufficient or reduced autophagic activity, resulting in 
harmful proteins aggregates/ accumulation of damage organelles, such as mitochondria, 
lysosomes, among others. Our results clearly show that when SIRT1 deacetylase is inhibited, 
occurs an increase of Beclin-1 acetylation in sAD cybrid cell line, which may be responsible for 
an impairment of autophagic machinery, seen in AD ailment. 
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This matter is in synchrony with our hypothesis, proving, at the same time the 
neuroprotective role of SIRT1 protein in neurological disorders.  
Afterwards, we noticed an increase of acetylated Beclin-1 basal levels in our sAD cybrid cell 
model, which may be a part of the source of a compromised autophagy-lysosomal pathway in AD. 
At same time, a significantly increase of acetylated Beclin-1 occurs more specifically in sAD 
group, when inhibited SIRT1deactylase. On the other hand, a decrease of acetylated Beclin-1 
happens in sAD group, when p300 acetyltransferase is inhibited, being in accordance with our 
theory.  
Acetylation is one of the most important post-translational protein modifications in the cell 
(Drazic et al., 2016), with a main role in several biological processes, such as transcriptional 
regulation, DNA damage repair, aging, cell cycle progression and glycolysis (Yi and Yu, 2012). 
Protein acetylation is an important regulatory mechanism, tightly regulated itself in response to 
metabolism changes, contributing to control of autophagy pathway. However, the role of 
acetylation in autophagy remains unclear. 
Another key protein in the autophagy machinery is LC3, a protein essential for 
autophagosome biogenesis, including formation, expansion, and cargo recruitment. In our data, 
we observed that in sAD cybrid cell lines untreated, a significantly decreased in autophagic flux 
occurs. 
Nevertheless, a slight increase in autophagic flux arises, when we used C646 in sAD cybrid 
cell line, suggesting that a deacetyled Beclin-1 by SIRT1 may normalize autophagy pathway flow 
in AD disorder. Moreover, SIRT1 deacetylase is essential for LC3 translocation to shift its 
distribution from the nucleus to cytoplasm during cell starvation (Huang and Liu, 2015). 
Simultaneously, p62 protein is used as a marker for autophagic flux, linking physically 
autophagic cargo to the autophagic membrane (Pugsley, 2017). p62 is localized to ubiquitin-
positive inclusions bodies, especially in liver and brain, a common phenomenon that can be 
observed in various diseases, such as neurodegeneration; and into membrane-confined 
autophagosomal and lysosomal structures. In this manner, p62 relates to the formation of ubiquitin-
positive inclusions bodies and binds LC3II to promote autophagic degradation (Liu et al., 2016). 
Additionally, immunostaining shows that p62 accumulates in early stages of NFTs formation in 
AD patients (Kuusisto, Salminen and Alafuzoff, 2002).  
Our findings show a significantly decrease of p62 flux levels in both MCI and sAD untreated 
cybrid cell lines. Besides, when p300 is inhibited an extreme increase of p62 flux occurs in sAD 
group, confirming that an acetylation of Beclin-1 may compromise autophagy pathway in AD 
pathology. As well, we demonstrated that accumulation of p62 protein in conjugation with a 
reduced autophagic flux designate an impairment of autophagic clearance in AD. 
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As a matter of fact, aberrant clearance of lysosomal substrates, including accumulation of 
AVs, has been noted in AD patients, reflecting a defect related with the progression of AD 
condition (Steele et al., 2013). Additionally, persuasive evidences have supported that autophagy 
dysfunction in AD may occurs due to defective lysosomal clearance (Yang et al., 2011). 
 It is well known that autophagy decreases with age, underlining the possibility that a 
compromised autophagic activity with aging process, may contribute to develop age-related 
disorders, such as neurodegeneration and metabolic defects (Martinez-lopez, Athonvarangkul and 
Singh, 2015). One common forms of autophagy pathway, CMA is responsible to ensure cellular 
homeostasis through the removal of damaged/malfunctioning intracellular proteins, and    gradual 
loss of CMA functions, as well the manifestations of aging phenotypes have been observed in 
physiological aging process (Zhang and Cuervo, 2008; Arias and Cuervo, 2011). However, 
pathological aging is related with severe CMA failure, which has been described in many age-
related disorders, such as neurodegenerative diseases. This CMA dysfunction may occur due to 
different facets of alterations in LAMP-2A level or functions (Wong, 2018).  
LAMP-2A is described as a receptor for CMA substrates, where substrate proteins bind to 
monomers of LAMP-2A at the lysosomal membrane, creating multimeric complexes required for 
substrate translocation into lysosomes (Orenstein and Cuervo, 2010). It has been reported that 
LAMP-2A deteriorates during aging in lysosomes due to post-transcriptional changes and not 
because of aging process itself (Salminen and Kaarniranta, 2009). 
In spite of, not all lysosomal pathways of proteolysis are equally affected by age (Cuervo 
and Dice, 2000). The rate of autophagy decreases with aging, which compromise both CMA and 
further LAMP-2A. Many neurodegenerative pathologies-linked pathogenic proteins that are 
substrates of CMA. Basically, these toxic proteins interact in aberrantly manner with CMA 
components during their degradation, leading to CMA blockage. Such CMA malfunction 
compromises LAMP-2A, resulting an alteration of dynamics in the trafficking and recycling of 
LAMP-2A from the lumen to the lysosomal membrane, as occurs in neurodegenerative diseases 
(Sjödin et al., 2016). It is well known that the lysosomal system is altered in AD almaint. 
Furthermore, a broad range of lysosomal network proteins were considered in the CSF from AD 
patients, such as LAMP-1, LAMP-2A, Rab3 and Rab7, which found to be significantly increased, 
when compared with age-matched controls (Armstrong et al., 2014). 
Our results show increased levels of LAMP-2A in untreated sAD cybrid cell line. These 
findings are in accordance with a plausible CMA decrease rate and a lysosomal dysfunction, 
already described in AD pathology (Koga, Kaushik and Cuervo, 2011). 
More interestingly, an inhibition of SIRT1 have an advantageous effect in LAMP-2A 
expression in treated MCI cybrids-prodromal phase, when compared with treated sAD cybrid cell 
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lines. Basically, this evidence emphasizes the SIRT1 deacetylase protective role in LAMP-2A 
expression in MCI group, which alternativetely not occurs after the condition is installed, in sAD 
group. 
However, an inhibition of p300 decreases LAMP-2A levels in treated sAD group, comparing 
with treated MCI group. These findings support, that acetylation process is a critically important 
mechanism for metabolic network. Consequently, is quite clear that a deacetylation of Beclin-1 by 
SIRT1 protein, appears to have a good positive impact in LAMP-2A expression, as well in both 
autophagic and lysosomal pathways, specifically in AD pathology. Although, upon inhibition of 
acetylation the degradation of metabolic enzymes recognized by CMA into lysosome might be 
affected (Xiong and Guan, 2012). For this reason, more experimental studies are needed to 
describe in detail our hypothesis. 
 On the other hand, an increased and altered intracellular distributions of lysosomal 
hydrolases have been seen in many degenerated neurons, especially in brain areas known to 
become affected in AD condition (Cataldo et al., 1991). CatD is a soluble lysosomal aspartic 
endopeptidase, essential in numerous physiological functions, including metabolic degradation of 
intracellular proteins, activation and degradation of polypeptide hormones and growth factors, 
activation of enzymatic precursors, processing of enzyme activators and inhibitors, brain antigen 
processing and regulation of programmed cell death (Benes, Vetvicka and Fusek, 2008). An 
abnormal immunoreactivity of CatD in SPs of AD patients has been reported  (Cataldo and Nixon, 
1990; Cataldo, Hamilton and Nixon, 1994). CatD has been associated with important factors of 
AD pathogenesis, such as APP (Ladror et al., 1994), APOE (Zhou et al., 2006) and Tau protein 
(Kenessey et al., 1997) . However, is described that CatD is not essential for APP processing in 
CatD knock-out mice (Saftig et al., 1996). It is necessary to understand whether the processing of 
both APOE and Tau proteins by CatD in the brain must be pathologically relevant. 
Some studies have been described that CatD polymorphisms (Touitou et al., 1994), have 
impact in intracellular routing and maturation of the proenzyme, being associated with AD 
pathogenesis (Ntais, Polycarpou and Ioannidis, 2004). Moreover, an impairment of lysosomal 
pathway has been demonstrated to occur in early stage of AD pathology, before the robust 
accumulation of NFTs and SPs. Our data shows that CatD protein levels in untreated sAD cells 
are significantly increased comparing with both CT and MCI cells. Although, when p300 is 
inhibited CatD levels decrease in sAD treated cybrid cell line. These results suggesting that 
acetylated Beclin-1 may compromise the lysosome organelle, affecting CatD enzyme proper 
function, leading to an extreme increase of levels expression. 
In addition, our theory reveals that a deacetylation of Beclin-1 plays a cytoprotective role in 
lysosomal pathway. Therefore, an upregulation of CatD protein expression in AD condition, may 
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represent a compensatory protective mechanism to counteract the autophagic-lysosomal deficit of 
the neurons in eliminating toxic protein aggregates. 
Abnormalities and progressive dysfunction of the endosomal-lysosomal network have been 
described as a signature feature of AD malady. Lysosomes become dysfunctional as a reflection 
by their enlargement as they accumulate autophagic and endocytic substrates (Nixon, 2017) . 
Rab7 is commonly viewed as a late endosome maker protein and involved in multiple 
processes, including early-to-late endosome transition, biogenesis of lysosomes, transport of 
autophagosomes to endosomes/ lysosomes, and vacuole fusion (Wen et al., 2017). 
Gutierrez et al. (Gutierrez et al., 2004) have described the function of Rab7 protein for the 
progression of autophagy in mammalian cells (Gutierrez et al., 2004). Although, an expression of 
a constuctively active form of Rab7 results in the formation of large perinuclear lysosome clusters, 
while dominant- negative Rab7 disperses lysosomes throughout the cytosol (Bucci et al., 2000). 
Interestingly, in basal forebrain, frontal cortex and hippocampus of MCI and AD patients, Rab7 
gene expression and proteins levels have been reported to be upregulated (Ginsberg, Mufson, et 
al., 2010). Lately, Rab7 protein levels were described to be increased in CSF of AD patients. Also, 
a new study reports that an increase of Rab7 in AD condition can enhance secretion of Tau protein 
(Rodriguez et al., 2017) . During our study, we observed an increase of Rab7 basal levels in sAD 
cybrid cell line, as expected. Additionally, further inhibition of SIRT1 over-increases Rab7 protein 
levels in sAD group. However, when we used C646, a decrease of Rab7 protein levels occurs, 
especially in sAD cells. These results are in accordance with our theory, that a deacetylated Beclin-
1 by SIRT1 deacetylase influences in a positive manner, regulating autophagy-lysosomal and 
endocytic pathways.  
Another, not less important protein is LAMP-1, a marker of lysosomes. It was shown that 
LAMP-1 protein levels are increased in AD brains, but its expression is inversely correlated with 
hyperphosphorylated Tau deposition in individual neurons with NFTs, one of the hallmarks of AD 
ailment (Wang et al., 2016). 
Additionally, we observed an increase of LAMP-1 basal expression in sAD cybrid cell line, 
as expected indicating a feedback mechanism to facilitate autophagosome clearance. Curiously, 
when we inhibited p300, a decrease of LAMP-1 clusters size in sAD group occurs, suggesting that 
acetylation process may be implicate in autophagy-lysosomal dysfunction. 
Furthermore, is clear that a deacetylation of Beclin-1 influences the improvement of both 
autophagy and lysosomal pathways in AD pathology. SIRT1 has protective role in different 
pathological conditions, especially in neurodegenerative diseases and its potential therapeutic 
effect in different pathways, may be a future focus on neurosciences. 
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6 CONCLUSION AND FUTURE PERSPECTIVES 
 
For decades, autophagy has been considered as an active death pathway, but only recently 
its cell survival functions have been underlined. Autophagy plays a crucial role in AD pathology. 
It is conceived that activation of autophagy may promote neuronal survival in physiological and 
pathological situations under a strictly regulated process, suggesting that increasing levels of 
Beclin-1 by gene therapy or by a drug acting at this level, could be a promising strategy. Our 
results clearly indicate that SIRT1 deacetylase mediated deacetylation of Beclin-1 may be a 
feasible strategy to overcame the defective autophagy-lysosomal pathway observed in AD 
condition. 
During these years, several studies have indicated that pharmacological induction of 
autophagy can be beneficial for treatment of neurodegenerative diseases, and increased autophagy 
has been shown to ameliorate pathology in various disease models by enhancing the clearance of 
intracytoplasmic protein aggregates, including hyperphosphorylated Tau protein. 
As a complex group of diseases, scientists are focus to understand how the nervous system 
works at the molecular and genetic levels, helping to develop more effective treatments for these 
maladies. However, medicines treat the symptoms of these pathologies, but cannot slow, prevent 
or reverse the progressive deterioration. 
We identify in this study, that a deacetylation of Beclin-1 in sAD cybrid cell line can improve 
the autophagy pathway flux, as well as the maturation of autophagosomes and finally lysosomal 
network. We show for the first time, in sAD cells, that acetylation-dependent regulatory 
mechanism can compromise autophagosome maturation and later lysosome compartment. 
Further work is needed to clarify in detail these mechanisms responsible for an autophagy-
lysosomal pathway dysfunction described in AD context. 
In summary, our current study on Beclin-1, indicates that acetylation, a post-translational 
modification, can occur at different stages of autophagy pathway. However, under a variety of 
conditions, autophagic response may be induced, inhibited or fine-tuning. 
Our research found a new therapeutic target, Beclin-1 since acetylation process is responsible 
for perturbing autophagy-lysosomal pathway, leading to an accumulation of autophagosomes, as 
well, inhibiting its maturation and promoting autophagic dysfunction in AD ailment. This 
approach allows for an intervention up-stream in the events leading to AD pathogenesis. 
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